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Abstract 
Predicting Opioid Prescribing Behaviors: 
Influence of an Expert Opioid-Risk Evaluation 
 
Alison M. Vargovich, M.S. 
Opioid analgesics have been shown to be effective for short-term pain reduction; however, 
chronic opioid therapy does not improve functioning, and may lead to problems with dependence 
and abuse.  Physicians report having difficulty discerning substance abuse or drug diversion, 
which can lead to over- or under- prescribing, poor pain management, and may contribute to the 
growing number of opioid-related overdose deaths.  The primary aim of this study was to 
determine if a psychological opioid risk evaluation influenced opioid prescribing in physicians at 
the West Virginia University (WVU) Family Medicine Clinic.  For this retrospective study, 
participants were 151 (89 female) adult patients being considered for long-term opioid therapy.  
Patients participated in a psychological opioid risk evaluation, which included several 
questionnaires and a clinical interview.  This evaluation resulted in an opioid risk level (i.e., low, 
low-moderate, moderate, moderate-high, high) being assigned to each patient representing 
clinical judgment about their potential risk for misusing or abusing opioid medication.  An 
electronic medical record review was conducted on each patient, abstracting information about if 
an opioid was prescribed, in addition to several other factors, which later were included in 
logistic regression analyses.  Patients prescribed an opioid were more likely to be married or with 
a long term partner and have a higher level of education.  Patients not prescribed an opioid were 
more likely to report a higher pain rating at the time of the evaluation, a history of abuse or 
substance abuse, or have higher total scores for questionnaires measuring pain catastrophizing, 
misuse or diversion behaviors, and depression symptoms.  Risk status and substance abuse 
history significantly predicted opioid prescribing, with a decrease in risk status resulting in an 
increase in opioid prescribing, and those with a history of substance abuse being less likely to be 
prescribed an opioid; however, substance abuse did not significantly improve the overall model 
and was removed.  Additionally, demographic variables (i.e., age, sex, ethnicity/race) were not 
significant predictors of prescribing as found in other studies.  These findings suggest that 
providing physicians with additional information about their patient’s opioid abuse potential aids 
in prescribing decisions and may reduce prescribing bias based on demographic factors.  Risk 
status may allow physicians to integrate evidence-based factors into their decision-making 
process in a simplified manner, and possibly improve patient care.  Future work should continue 
to address physicians’ prescribing perspective, accuracy of evaluations, effect on patient care, 
and cost analyses for the healthcare system.   
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Predicting Opioid Prescribing Behaviors: 
Influence of an Expert Opioid-Risk Evaluation 
Treatments for chronic pain include a variety of pharmacological and non-
pharmacological options, with opioid analgesics being a common treatment option (Turk et al., 
2011).  The evidence for opioid analgesics supports short-term usage; however, long-term opioid 
therapy has mixed results with some research indicating minimal pain reduction, and little to no 
evidence for improvement in functioning (Furlan et al., 2006).  Other treatments that are 
effective in alleviating chronic pain include pharmacological, rehabilitative, medical, and 
psychological treatment options, with surgical options being a less effective solution (Turk et al., 
2011).  While opioid analgesics commonly are used in the treatment of chronic pain, there has 
been an increase in misuse and abuse, as well as opioid-related overdose deaths across the United 
States (Substance Abuse and Mental Health Services Administration, 2007; Warner et al., 2009).  
Physicians are in a difficult position attempting to provide chronic pain patients with the best 
possible care, while assessing patients for potential substance abuse and other issues.  
Additionally, physicians report feeling unprepared to assess for substance abuse issues and 
express concern over potential litigation for inappropriate prescribing of opioids (Matthias et al., 
2010; Richeimer, 2005).  With chronic pain becoming one of the most common reasons patients 
present for care (Cherry, Burt, & Woodell, 2003), it is essential for physicians to understand the 
nature and treatment of this condition.   
Conceptualization of Chronic Pain 
Chronic pain is defined as “pain which has persisted beyond normal tissue healing time,” 
which typically requires persistence of at least three months (International Association for the 
Study of Pain, 1986).  This definition does not account for the quality, type, and severity of such 
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pain, which limits its utility, both clinically and in research.  Purves et al., (1998) proposed a 
more comprehensive description, suggesting chronic pain be defined as  “current continuous or 
intermittent pain or discomfort which has persisted for more than three months, with recent or 
frequent seeking of treatment or use of analgesic medication.”  While this definition is not 
without flaws, it provides greater differentiation between those with acute and chronic pain.  By 
identifying patients with chronic pain, health care professionals are better able to make treatment 
decisions and assess patients’ progress over time.  
Chronic pain is the most common reason patients seek medical services (Cherry, Burt, & 
Woodell, 2003); however, estimates of prevalence vary greatly from study to study, with rates as 
low as 7.6% and as high as 45%, with a median of 15% (Bowsher, Rigge, & Sopp, 1991; 
Brattberg, Thorslund, & Wikman, 1989; Croft, Rigby, Boswell, Schollum, & Sillman, 1993; 
Crook & Browne, 1984; James, Large, Bushnell, & Wells, 1991; Smith, Read, Grimshaw, Watt, 
& Chambers, 1996; Von Korff, Dworkin, & Le Resche, 1990; Verhaak, Kerssens, Dekker, Sorbi, 
& Bensing, 1998).  Hardt, Jacobsen, Goldberg, Nickel, and Buchwald (2008) examined data 
from 10,291 respondents to the National Health and Nutrition Examination Survey, finding 
chronic pain estimates were 10.1% for back pain, 7.1% for pain in the legs/feet, 4.1% for pain in 
the arms/hands, and 3.5% for headache.  Chronic regional pain accounted for 11.0% of the 
sample and chronic widespread pain, 3.6%.  As found in other studies (Bassols, Bosch, 
Campillo, Canellas, & Banos, 1999; Bowser et al., 1991; James, Large, Bushnell, & Wells, 1991; 
Von Korff, Dworkin, Le Resche, & Kruger, 1988), women had higher rates than men for 
headache, abdominal pain, and chronic widespread pain.  While up to 45% of the population may 
suffer from chronic pain, health services utilization suggests that between 10-15% of the 
population suffers from clinical chronic pain (i.e., chronic pain that has been diagnosed 
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clinically; Smith, Hopton, & Chambers, 1999).  Thus, the majority of individuals reporting issues 
with chronic pain may not be seeking medical services.        
Chronic pain patients who are seeking health care services are managed through 
specialist pain clinics, medical specialties (e.g., orthopedics), and a vast majority through 
primary care (Clinical Standards Advisory Group; Crombie & Davies, 1998; Sullivan, Turner, & 
Romano, 1991).  One study mailed a survey to primary care providers in eight community clinics 
and found that 37.5% of adult appointments in a typical week involved patients with chronic pain 
complaints (Upshur, Luckmann, & Savageau, 2006).  Twenty percent of chronic pain patients 
presenting to primary care have pain due to malignancy; however, of the non-malignant chronic 
pain patients approximately 50% have limb and joint pain and approximately 33% present with 
back pain (Bowsher et al., 1991; Brattberg et al., 1989; Smith, Hopton, & Chambers, 1999).  
Treatment of chronic pain often is complicated by multiple factors that contribute to the clinical 
presentation.  General physical health and psychological (e.g., depression) and psychosocial 
factors are associated with chronic pain symptoms (Arnow et al., 2009; Bair, Wu, Damush, 
Sutherland, Kroenke, 2008; Haley, Turner, & Romano, 1985; McCracken, Gross, Aikens, & 
Carnrike, 1996; Spitzer, LeBlanc, & Debuis, 1987).  Because of these multiple contributors, 
there are several different treatment options that have demonstrated effectiveness in alleviating 
chronic pain, including pharmacological, medical, psychological, and other interventions.  For 
further information on non-opioid treatments for chronic pain see Appendix A.     
Opioid Treatment for Chronic Pain 
 Opioids are pain relieving medications, which bind to opioid receptors found in the brain, 
spinal cord, gastrointestinal tract, and other organs in the body (National Institute on Drug 
Abuse, 2011).  After binding, they act to reduce the perception of pain, decrease the reaction to 
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pain, and increase pain tolerance (National Institute on Drug Abuse, 2011).  Furlan, Sandoval, 
Mailis-Gagnon, and Tunks (2006) evaluated 41 randomized controlled trials in a meta-analysis 
to determine the effectiveness of opioids for the treatment of various chronic pain conditions, 
including osteoarthritis, diabetic neuropathy, low-back pain, and rheumatoid arthritis.  The 
authors concluded that opioids are capable of small reductions in pain severity and functional 
improvement as compared to placebo; however, when compared to other analgesic medications, 
they have similar reduction in pain, but less improvement in function.  Trescot and colleagues 
(2008) found weak evidence for the use of morphine and transdermal fentanyl for long-term 
opioid therapy of six months or longer in managing chronic non-cancer pain; however, they 
concluded there was limited evidence for all other controlled substances, including the most 
commonly used drugs, oxycodone and hydrocodone.  Therefore, there was not enough evidence 
to determine that other controlled substances should or should not be used for long-term opioid 
therapy.  Two other systematic reviews concluded that due to the paucity of research on the 
effectiveness of long-term opioid therapy, opioids should be used infrequently and when 
prescribed only should be used for short-term pain relief (Manchikanti, 2004; Neush, Rutjes, 
Husni, Welch, & Juni, 2009).  Guidelines from two major pain associations (i.e., Neuropathic 
Pain Special Interest Group of the International Association for the Study of Pain; European 
Federation of Neurological Societies Task Force) recommend that opioids be reserved for the 
second- or third-line of treatment in pain problems, but can be utilized as a first-line treatment 
for episodic exacerbation of severe neuropathic pain (Attal et al., 2010; Dworkin et al., 2010). 
While the long-term use of opioids is not supported by the current literature on chronic pain, 
opioids remain the most potent analgesics available, and continue to be utilized for pain 
management (Furlan et al., 2006). 
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Prevalence of Prescription Opioid Abuse in the U.S. 
In recent years, the overall utilization of pharmaceuticals in the United States has greatly 
increased with the average of all states up to 11.5 annual prescriptions per capita (IMS Health, 
2012).  This general increase includes controlled substances which have averaged a 7% increase 
from 2010 to 2011.  A growing public health concern is the abuse, dependence, and misuse of 
prescription pain relievers in the United States.  The National Survey on Drug Use and Health 
(2007) reported that 12.5 million Americans used prescription pain relievers for nonmedical 
purposes, an increase of 1.5 million from 2002.  Approximately 70.2% of individuals who abuse 
prescription opioids obtain the pills from friends or relatives by stealing, buying, or getting the 
medication for free.  Of these recreational users, 81.7% indicated that the opioids originated with 
a prescription (Substance Abuse and Mental Health Services Administration, 2008).  
Surprisingly, based on a 2009 survey of teenagers’ access to substances, prescription drugs 
reportedly are easier to obtain than beer (The National Center on Addiction and Substance Abuse 
at Columbia University, 2009).   In addition to the increase in opioid misuse, the number of 
patients admitted to substance abuse treatment facilities for nonheroin opiates and opioid abuse 
increased four-fold from 23,000 to more than 90,000 from 1999 to 2007 (Substance Abuse and 
Mental Health Services Administration, 2007).  With significant increases in opioid prescriptions 
and opioid misuse, there also has been a rise in prescription opioid overdoses.  The Centers for 
Disease Control and Prevention reported that 4,000 people died from opioid overdoses in 1999.  
This number has more than tripled with nearly 15,000 people dying from opioid overdoses in 
2008 (Warner, Chen, & Makuc, 2009).   
 Opioid misuse is a common problem across the United States, with special concern in 
West Virginia.  In a state by state comparison conducted in 2011, WV ranks eighth in overall 
PREDICTING OPIOID PRESCRIBING BEHAVIOR      
     
6 
prescription of controlled substances, with Monongalia county ranking among the highest 
counties in WV (IMS Health, 2012).  After dissecting opioid prescribing by specialty in WV, 
family medicine ranked the highest with approximately 1,000 prescriptions in 2011 with the 
second highest being internal medicine at approximately 600 prescriptions (IMS Health, 2012).  
The Centers for Disease Control and Prevention reported that WV was ranked second in the U.S. 
for overall opioid drug overdose deaths after examining data from 1999-2008 (Center for 
Disease Control and Prevention, 2011b).  These statistics indicate that opioid misuse is an 
increasing problem across WV and the United States.  
Cost of pain.  When calculating the cost of pain to society, micro factors have to be 
extrapolated to the macro level.  Understanding the required medical treatment, complications 
for other health problems, and decreased worker productivity is necessary to estimate the 
national costs.  Gaskin and Richards (2012) utilized the 2008 Medical Expenditure Panel Survey 
to estimate cost of pain in the United States.  Pain problems included both acute and chronic pain 
issues.  The authors found that pain costs range from $560 to $635 billion which is larger than 
the annual costs of heart disease ($309 billion), cancer ($243 billion), and diabetes ($188 
billion).  Interestingly, individuals with pain average an additional $261 to $300 each compared 
to individuals without pain.  These estimates included health care costs attributed to pain and 
lower work productivity due to pain.  Birnbaum and colleagues (2011) specified their research to 
the costs associated with prescription opioid abuse finding estimates close to $55.7 billion in 
2007, an increase of $2.3 billion from estimates a year earlier (Hansen, Oster, Edelsberg, Woody, 
& Sullivan, 2011).  This estimate consists of workplace costs accounting for $25.6 billion (46%), 
health care costs for $25.0 billion (45%), and criminal justice costs for $5.1 billion (9%).  With 
PREDICTING OPIOID PRESCRIBING BEHAVIOR      
     
7 
opioid prescribing and misuse continuing to rise, the cost of pain to society stands to increase as 
well.  
Influence of Policy on the Healthcare System and Opioid Prescribing 
In an attempt to slow the growth of opioid abuse, 34 states have initiated prescription 
drug monitoring programs to identify drug abuse and diversion (Drug Enforcement 
Administration Office of Diversion Control, 2011).  Diversion includes using prescriptions for 
recreational purposes, sharing or selling prescriptions with family members or friends, and any 
other use not intended when prescribed (Gilson, Ryan, Joranson, & Dahl, 2004).  In 2011, the 
White House Office of National Drug Control Policy released a Prescription Drug Abuse 
Prevention Plan focusing on education, monitoring, proper disposal, and enforcement to reduce 
prescription drug abuse.  First, education is aimed at increasing awareness about the dangers of 
prescription drug abuse and information about how to properly dispense, store, and dispose of 
controlled substance medications.  Second, increased monitoring includes the use of prescription 
drug monitoring programs and requiring patients to obtain controlled substances from one 
provider.  Third, developing and implementing consumer-friendly and environmentally-
responsible disposal programs aims to decrease “left-over” opioids from being misused.  Lastly, 
providing law enforcement agencies with the means necessary to prevent physicians from 
overprescribing and stop drug seeking patients from “doctor shopping” (White House 
Prescription Drug Abuse Prevention Plan, 2011).  These nationwide changes are meant to 
decrease opioid drug abuse and reduce overdose deaths.   
As of July 2012, WV practitioners are required to conduct an initial search of the “West 
Virginia Controlled Substances Monitoring Program database for information regarding specific 
patients for whom they are providing pain-relieving controlled substances as part of a course of 
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treatment for chronic, nonmalignant pain but who are not suffering from a terminal illness” 
(West Virginia Code, 2012).  The information obtained from this search must be documented in 
the patient’s medical record.  Additionally, the mandate requires annual checks for these patients, 
with continued monitoring and documentation.  Additionally, the Food and Drug Administration 
recently has required opioid manufacturers to develop a Risk Evaluation and Mitigation Strategy 
to manage potentially risky prescription drugs and ensure that the benefits of such drugs 
outweigh the risks (Food and Drug Administration Department of Health and Human Services, 
2008).  By establishing these policies, the transaction costs for the patient increase. Transaction 
costs are applied to economic models and the healthcare system referring to buying and selling, 
but also to interpersonal and system interactions (Coase, 1937; Rice, 1998; Stiles, Mick, & Wise, 
2001).  More specifically, the frequency, specificity, uncertainty, limited rationality, and 
opportunistic behavior associated with various interactions. In this situation, the transaction costs 
refers to the increase in barriers (i.e., “costs”) to obtaining opioids by the patient and prescribing 
these medications long-term for the physician. By increasing the transaction costs for patients, it 
may result in a decrease in patients that misuse or abuse opioids presenting to clinics with more 
regulations and guidelines as it would be too difficult to obtain a prescription.  The purpose of 
these mandates is to decrease opioid abuse, lessen the costs on the health care system, and 
decrease inappropriate prescribing of opioids; however, it may lead to indirect harm of patients.  
With greater attention on decreasing opioid misuse, legislation and policy may act to 
increase physicians’ fear of prescribing opioids (i.e., opiophobia) and inadvertently punish 
patients who are using their medications appropriately.  Opiophobia is described as the fear that 
appropriate opioid use will lead patients to become addicted to the medication, which results in a 
failure to prescribe opioids due to the overestimation of risks, and therefore potentially under-
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treating a patient’s pain (Bennett & Carr, 2002; Morgan, 1985; Nathan, 2008).  Physicians are 
asked to determine if patients are malingering about their pain, a question, which many 
physicians have reported, they are not adequately trained to assess (Richeimer, 2005).  As a 
result, they may avoid prescribing opioids in order to circumvent potential litigation.  Medication 
issues (e.g., inappropriate prescribing, over-prescribing, under-prescribing) are listed as one of 
the top ten reasons why physicians are sued (Nathan, 2008).  With the addition of stringent 
policy, the possibility for litigation increases and many physicians may feel the potential risks of 
prescribing opioids outweigh the benefits.  Physician opiophobia may decrease inappropriate 
opioid prescribing at the cost of harming the patients who are using opioids appropriately and are 
benefiting from the medication. 
Furthermore, the relationship between physicians and chronic pain patients can be 
conflictual and complicated.  Physicians may feel pressured to treat the pain with opioids, have 
difficulty evaluating the veracity of the patients’ reports of pain, and worry about diversion of 
opioids and misuse or abuse (Matthias et al., 2010).  Additionally, because of the chronic and 
complicated nature of chronic pain, physicians report feeling frustrated, overwhelmed, and/or 
ungratified, when discussing care for patients with chronic pain (Matthias et al., 2010).  
Alternatively, chronic pain patients report a strong desire to be believed by their physician, citing 
a label or diagnosis as a confirmation of their chronic pain experience (Clarke & Iphofen, 2005).  
Thus, with physicians required to question the veracity of a patient’s pain report and the patient 
seeking confirmation of their pain experience, conflictual encounters are likely to occur.  As a 
result of the complicated and conflictual relationship, clinical care is negatively affected with 
patients on chronic opioid therapy having a significantly lower incidence of receiving preventive 
services, specifically cervical and colorectal cancer screenings (Buckley, Calvert, Lapidus, & 
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Morris, 2010).  Caring for patients with chronic pain on chronic opioid therapy is time-
consuming.  Due to the high rate of opioid misuse, physicians often approach these patients with 
a more critical perspective and are required to question the patient’s medication behaviors to 
ensure appropriate usage (Bendtsen, Hensing, Ebeling, & Schedin, 1999; Bertakis, Azari, & 
Callahan, 2003).  This type of patient-clinician relationship may contribute to the increased 
likelihood of those on chronic opioid therapy discontinuing care at a clinic, initiated by either 
themselves or the clinic (Buckley et al., 2010).  By requiring physicians to further question 
patients on chronic opioid therapy and approach patients with distrust, the patient-clinician 
relationship endures more strain and potential for conflict. 
Need for Evaluations to Determine Appropriateness  
A potential means to ameliorate the conflictual relationship between physicians and 
patients on chronic opioid therapy is by engaging other professionals in the health care team 
(e.g., psychologist, social worker).  A pain consultant has the ability to provide an expert 
assessment of the patient’s type, quality, intensity, and severity of pain as well as providing 
treatment recommendations tailored to the patient’s pain problem.  Additionally, a pain 
consultant and their evaluation can provide the physician with a means to raise concerns and 
discuss difficult topics about the patient’s treatment and behavior without damaging the 
relationship.  This approach allows the physician to maintain rapport with a patient and continue 
to provide care in a potentially difficult situation by referring to a third party source of 
information (i.e., pain consultant), rather than having the patient place blame on the physician 
which may lead to feelings of distrust and resentment.  Furthermore, the use of an opioid-risk 
evaluation provides physicians with potential risk and protective factors to consider prior to 
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prescribing an opioid, easing the decision making process and offering potential protection 
against litigation. 
Factors related to potential opioid misuse.  Research on patient characteristics associated 
with opioid misuse suggests there are several factors that are important to consider prior to 
prescribing.  The American Pain Society and American Academy of Pain Medicine released 
Clinical Guidelines in 2009 for the use of chronic opioid therapy in patients with chronic non-
cancer pain.  It was recommended that patient history, physical examination, assessment of the 
patient’s family history, psychosocial factors, personal and familial history of substance abuse, 
patient age, and psychiatric comorbidities be evaluated prior to prescribing chronic opioid 
therapy (Chou, 2009).   
Pergolizzi and colleagues (2012) support these criteria and recommend continued 
monitoring and assessment of these characteristics over the course of treatment as well as 
monitoring of aberrant drug taking behaviors.  Continued monitoring and assessment is 
recommended because of the dynamic nature of the criteria (e.g., emergence of mental health 
condition, unemployment, divorce), thus the potential for risk status to change overtime.  
Aberrant drug taking behaviors have been placed in four general categories: prescription requests 
(e.g., early refill requests, lost pills, visits to the emergency room to obtain opioids), use of 
medication for non-prescribed purposes (e.g., illicit drug use, using opioids to treat anxiety or 
depression symptoms), illegal behaviors (e.g., stealing drugs, selling prescription drugs), and 
other signs or behaviors (e.g., multiple dose escalations without prior authorization, concurrent 
use of alcohol, hoarding drugs; Pergolizzi, 2012).  All of these criteria have been found to be 
potential signs of current or future opioid misuse among chronic pain patients (Breitbart et al., 
1997; Passik, Messina, Golsorkhi, & Xie, 2010; Portenoy, 1996; Turk, Swanson, & Gatchel, 
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2008; Weaver & Schnoll, 2002; Ziegler, 2005).  Physicians are encouraged to utilize drug-
screening tests and patient self-report to assess for aberrant behaviors; however, patients who are 
misusing medication are not likely to report this information to the physician.  Additionally, all 
clinicians treating chronic pain patients with opioids should recognize that all patients are at 
some degree of risk because of the evidence that simply taking opioids is a risk factor for misuse 
and abuse (Edlund, Sullivan, Steffick, Harris, & Wells, 2007; Jamison, Kaufmann, & Katz, 
2000).  Rice and colleagues (2012) proposed a model to identify patients at risk for prescription 
opioid abuse, dependence, and misuse.  They found that the following characteristics were most 
predictive of abuse: male gender, prior opioid prescriptions, at least one prior prescription of 
buprenorphine or methadone, at least one diagnosis of non-opioid drug abuse, mental illness, 
hepatitis, or having a family member diagnosed with opioid abuse.  While the assessment and 
monitoring of risk factors is an important consideration when treating chronic pain patients on 
long-term opioid therapy, it does not have to prevent the prescription of opioids.  Research 
suggests that even patients with an active opioid addiction may be successfully treated with 
opioids; however, it requires closely monitored conditions, which may require more care than a 
physician is able to provide (Weaver & Schnoll, 2002). 
Medication Prescribing Decisions and Behaviors 
 The research examining prescribing behaviors and decision-making has focused on 
factors that influence physician’s decision making process, how patient characteristics (e.g., race, 
ethnicity) may influence prescribing, and physician characteristics and training.  Nair, 
Manchanda, and Bhatia (2010) found that physician prescribing behavior is significantly 
influenced by the behavior of research-active specialists in the physician’s reference group.  
Therefore, physicians are more likely to model their prescribing behavior after a respected 
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specialist that is known to them.  In a study examining physicians’ opioid knowledge, beliefs, 
attitudes and prescribing practices, the authors found that physicians held many misconceptions 
about the prescribing of opioids (e.g., appropriateness of prescribing opioids for chronic pain, 
characteristics of addiction) and reported that fear of investigation led them to lower the dose 
prescribed, limit the number of refills, or prescribe a Schedule III or IV rather than a Schedule II 
opioid (Wolfert, Gilson, Dahl, & Cleary, 2010).  This information suggests that physicians may 
be more likely to modify their prescribing behaviors out of fear of legal recourse rather than 
based on patient characteristics.    
Additionally, studies have shown that ethnic and racial minorities are less likely to be 
prescribed opioid analgesics than white patients (Olsen, Daumit, & Ford, 2006; Pletcher, 
Kertesz, Kohn, & Gonzales, 2008; Tamayo-Sarver, Hinze, Cydulka, & Baker, 2003).  Burgess 
and colleagues (2008) expanded upon this research by examining race combined with patients 
exhibiting challenging and non-challenging behaviors, with challenging behaviors being 
described as the patient being aggressive about his need for stronger pain medication, asking for 
drugs by name, reporting that he tried his wife’s prescription for Percocet, and being highly 
expressive about his pain and his need for relief.  The authors found that physicians were more 
likely to prescribe a higher dose or a stronger opioid for black patients exhibiting challenging 
behaviors than non-challenging behaviors.  Interestingly, the result was opposite for the white 
patients, with physicians more likely to prescribe higher doses or a stronger opioid for non-
challenging patients.  Another study showed that male physicians prescribed more opioids to 
white patients, while female physicians prescribed more opioids to black patients (Weisse, 
Sorum, Sanders, & Syat, 2001).  Lastly, Hirsh, George, and Robinson (2009) demonstrated that 
sex, race, age, and pain expression cues accounted for significant variance in decision making 
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among nurses prescribing opioids in a virtual human model.  In this study, females, African 
Americans, older patients, and patients expressing high pain via facial expressions were more 
likely to be prescribed an opioid.   
Several physician and practice characteristics also influence opioid prescribing, including 
age, knowledge about treating pain, and beliefs and attitudes about opioids.  Younger age seems 
to be associated with more “liberal” views on prescribing opioids (e.g., favor earlier intervention 
for pain control, more patient control over analgesics); however, this study examined prescribing 
in chronic cancer pain (Cleeland, Cleeland, Dar, & Rinehardt, 1986).   This result later was 
found in prescribing for non-cancer chronic pain, with younger age being associated with 
prescribing opioids (Hutchinson, Moreland, de Williams, Weinman, & Horne, 2007).  Another 
study found that previous experiences with patients addicted to drugs significantly influenced 
opioid prescribing, with physicians being less likely to prescribe opioids for fear of contributing 
to abuse or dependence (Dobscha, Corson, Flores, Tansill, & Gerrity, 2008).  Additionally, 
physicians unwilling to prescribe opioids held stronger beliefs that prescribing would lead to 
patient abuse, addiction, and potential legal recourse (Nwokeji, Rascati, Brown, & Eisenberg, 
2007).  Glajchen (2001) reviewed barriers to treating chronic pain finding that lack of knowledge 
about opioids, negative attitudes toward prescribing opioids, and inadequate pain-assessment 
skills resulted in decreased opioid prescribing and poor pain management.  Two other studies 
corroborated these conclusions finding physicians were dissatisfied with their training on pain 
(Hutchinson et al., 2007) and opioid prescribing was determined by personal beliefs about 
opioids, with those with at least a moderate belief in the effectiveness of opioids being more 
likely to prescribe (Hutchinson et al., 2007; Nwokeji et al., 2007).  Physician misconceptions and 
inadequate pain management training, fear of legal recourse, lack of knowledge about laws and 
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regulations, and certain patient characteristics may result in decreased opioid prescribing and 
inadequate management of pain. 
Research addressing the complex problem of opioid misuse and opioid prescribing 
behaviors and their implications on societal costs and health care policy is important and has the 
potential to be quite impactful.  The long-term goal of the current project is to improve our 
understanding of opioid prescribing decisions made by physicians and to use that information to 
inform prescriber education and health care policy.  Understanding the interplay of chronic pain, 
opioid misuse, and opioid prescribing is critical for clinicians and researchers addressing this 
public health problem.  This project provides a more thorough conceptualization of influences on 
opioid prescribing decisions, and an understanding of how to better avoid opioid misuse in 
chronic pain patients and how best to communicate potential risk and need to physicians. 
Statement of the Problem 
  More thorough investigation of opioid prescribing behaviors could prove important for a 
numbers of reasons.  First, prescription overdose deaths have seen a dramatic increase over the 
past 15 years, eclipsing both cocaine and heroin overdose deaths (Center for Disease Control and 
Prevention, 2011a).  This increase is in part due to misguided views of prescription medication 
as being “safe” by the public; however, as overdose deaths have increased so have the number of 
prescriptions written by physicians (Center for Disease Control and Prevention, 2011c).  With 
the high stress associated with patient care, physicians may not have the time or resources to 
adequately assess patients prior to prescribing (Matthias, 2010).  As a result, physicians may 
under- or over-prescribe opioid analgesics resulting in inadequate management of pain.  With an 
increased understanding of opioid prescribing decisions, overprescribing or incorrect prescribing, 
which can lead to overdose deaths, could potentially be reduced.  Thereby, improving patient 
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care and providing individuals with the most appropriate treatment interventions for their 
specific condition.   
Second, physicians often lack training in discerning substance abuse or drug diversion 
(i.e., the use of prescription drugs for recreational or non-prescribed purposes) in patients and 
report feeling unprepared to coordinate care for patients with substance abuse and/or other 
psychological problems (Glajchen, 2001; Richeimer, 2005).  A logical solution seems to be to 
provide physicians with an expert pain psychologist’s assessment of the patient’s potential for 
use and misuse; however, this solution has not been evaluated in the literature.  If successful, an 
expert opioid-risk evaluation may alleviate some of the strain on the physician-patient 
relationship by improving physician knowledge of their individual patient.  Additionally, when a 
patient needs to be denied opioid analgesics for chronic pain, the physician can utilize the 
consultant’s evaluation as a means to avoid blame, and attempt to maintain the patient-physician 
relationship, while providing alternative treatments.      
Third, better understanding of how specific variables influence opioid prescribing in 
regard to opioids, especially an expert opioid-risk evaluation, will inform the protocol for 
prescribing controlled substances and have implications for larger health care policies.  Factors 
that significantly influence physician prescribing of opioids could be targets of efforts to reform 
policy, such as including more psychologists in the medical setting and increasing coverage of 
mental health evaluations and interventions by insurance companies.   
Previous research has demonstrated that physician qualities (e.g., beliefs about opioids 
for treating chronic pain) and patient characteristics (e.g., ethnicity/race) influence prescribing 
behaviors (Glajchen, 2001; Hutchinson et al., 2007; Nwokeji et al., 2007; Olsen et al., 2006; 
Pletcher et al., 2008; Tamayo-Sarver, 2003; Wolfert et al., 2010).  Moreover, it seems to be 
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affected by “opinion leaders” or specialists in the physician’s reference group, with physicians 
being more likely to imitate the prescribing behavior of specialist physicians (Nair et al., 2010).  
Knowing that physicians are more likely to follow the opinion of a specialist physician suggests 
that they may modify their prescribing behavior when presented with a psychologist’s expert 
assessment; however, this scenario has not been addressed in the literature.  Additionally, there is 
a limited literature addressing how factors outside of the physician influence opioid prescribing 
behaviors and how patient factors guide physicians’ script writing.  Establishing these 
associations is a critical step in understanding the complex nature of physician prescribing 
behavior and will afford a more thorough understanding of potential means to decrease 
overprescribing and improve patient care. 
The effect of opioid prescribing decisions on patients and the larger issue of public health 
substantiate the importance of further examination.  Although there is research that has examined 
physician characteristics that influence prescribing, there are few studies that explicitly target 
opioid prescribing and factors outside of the physician.  Consequently, a crucial need in this area 
is the investigation of opioid prescribing behaviors. The present study is designed to determine if 
the results of an independent opioid risk evaluation influence prescribing decisions and to further 
explore other variables, outside of the physician, that may impact prescribing decisions.  
Research Questions 
The current study was largely exploratory in nature as there has not been an examination 
of the influence of an opioid risk evaluation on opioid prescribing behavior.  As such, a priori 
hypotheses are not appropriate.  The current investigation of the influence of opioid risk-status 
and patient characteristics on opioid prescribing behavior had four major research questions: 
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1. Were patients who were prescribed opioids at the first appointment following the opioid 
risk evaluation different from those who were not prescribed an opioid?  The groups may 
differ on the self-report measures, with the former group having lower scores than the 
latter on the Pain Catastrophizing Scale, Screener and Opioid Assessment for Patients 
with Pain-Revised, Pain Disability Index and Beck Depression Inventory-II.  
Additionally, patients may differ on demographic variables, such as level of education.    
2. Did the patient’s opioid risk status affect whether a physician prescribed an opioid at the 
first appointment following the evaluation?  Each patient was ascribed a risk level (i.e., 
low, low-moderate, moderate, moderate-high, or high risk) following the risk evaluation.  
The physician may use this information when prescribing an opioid, and potentially, 
those ascribed a higher risk category are less likely to be prescribed an opioid.  
3. What other variables influenced physician opioid prescribing behavior?  Based on the 
literature, history of substance abuse, family history of substance abuse, cigarette 
smoking, mental illness, and being male are associated with opioid misuse.  Examination 
of these variables as they relate to predicting physician prescribing behavior may provide 
valuable information. 
4. How did the inclusion of opioid risk status and other significant variables (as determined 
in research question three) affect whether a physician prescribed an opioid at the first 
appointment following the opioid risk evaluation?  Analyses resulted in a comprehensive 
model of variables predicting physician prescribing behaviors.  
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Methods 
Study Design 
 Between October, 2010 and March, 2013 chronic pain patients requesting or being 
considered for opioid pain medication presenting to the West Virginia University Department of 
Family Medicine clinic were referred to the Family Medicine psychology team for an opioid risk 
evaluation.  Attending physicians are expected to refer patients for opioid risk evaluations, while 
resident physicians are required to refer their patients upon presentation for chronic opioid 
therapy.  The patients had a chronic pain condition diagnosed by their primary care physician 
prior to the evaluation; however, the duration of the chronic pain varies across patients, all 
meeting the minimum requirement of lasting longer than three to six months.  These patients 
were asked to participate in a clinical interview and to complete a number of self-report 
measures (described below) to assess for potential psychopathology, current functioning with 
pain, and potential for opioid abuse or misuse.  The present study, utilizing a retrospective cohort 
design, followed up on the outcome of those opioid risk evaluations by way of electronic medical 
record review.  Opioid risk status, whether or not the patient was prescribed an opioid, various 
demographic factors, and pain condition were abstracted from electronic medical records for 
each patient.  Physician’s decision to prescribe or not prescribe an opioid analgesic was 
compared across patients with varying levels of opioid risk status and a predictive model was 
developed to better explain the factors which may be influencing a physician’s decision to 
prescribe.  
Participants 
Participants were adult (age ≥ 18 years at the time of the evaluation) patients who 
reported to the West Virginia University Department of Family Medicine clinic for an opioid risk 
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evaluation conducted by a psychologist or psychology trainee.  The patients were referred to the 
Family Medicine psychologists because he or she was being considered for opioid therapy for a 
chronic pain condition.  As outlined by the Family Medicine Clinic policy, prior to prescribing 
long-term opioids, the resident physicians at the Family Medicine clinic are required to refer 
patients for an opioid risk evaluation and the attending physicians are expected to refer patients. 
(See Appendix B for additional information on the Family Medicine procedure).  These 
evaluations were conducted by one of the following individuals: faculty/licensed psychologist, 
postdoctoral psychologist, predoctoral intern, clinical or counseling psychology graduate student.  
All unlicensed psychologists, interns, or graduate students were supervised by a licensed 
psychologist who directly observed either in the room or via a video camera viewing system.  At 
the time of the patient’s visit, he or she completed a number of self-report instruments related to 
pain quality, intensity, and duration, functioning affected by pain, negative cognitions about 
pain, fear of activity and movement, risk for future misuse of opioids, current behaviors 
indicating medication misuse, and mood, in addition to a short demographic questionnaire.  The 
patients also participated in a clinical interview conducted by a psychologist or trainee to better 
understand his/her pain triggers, goals for pain and function, impact of pain on functioning, pain 
treatment history, social and family history, and personal and familial substance abuse history.   
Initially, electronic record reviews were conducted on 158 patients; however, seven cases 
were excluded due to having two opioid risk evaluations in their record; therefore the evaluation 
that took place at a later date was removed and the first evaluation chronologically was utilized 
in the study.  Opioid risk evaluations included in this sample totaled 151 (59% female) patients.  
Based on guidelines established by Hosmer and Lemeshow (2000), a minimum number of 10 
cases per independent variable are recommended for conducting a logistic regression, with a 
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preferred case-to-variable ratio of 20 to 1.  By including 151 patients, the analyses can include 
between 7-15 independent variables in the final predictive model.  These patients were further 
categorized based on their opioid risk status with 36 (23.8%) recorded as low risk, 14 (9.3%) as 
low-moderate risk, 39 (25.8%) as moderate risk, 19 (12.6%) as moderate-high risk, and 43 
(28.5%) as high risk.  Due to unequal sample size in each category resulting in small cell sizes 
for analyses, the low and low-moderate group was combined and the moderate and moderate-
high group was combined.  These changes resulted in the following categories: 50 (33.1%) 
recorded as low/low-moderate risk, 58 (38.4%) as moderate/moderate-high risk, and 43 (28.5%) 
as high risk.  See Tables 1 and 2 for information about referrals, risk status, and evaluations. Of 
note, it may appear when examining Table 2 that there are differences in the assigned risk status 
and the psychologist/trainee; however, these potential differences seem to be related to the 
scheduling process and characteristics of the psychologist/trainee.    
 Generally speaking, participants of the project were residents of Morgantown and 
surrounding areas of West Virginia and Pennsylvania and represent the ethnic and racial make-
up of the Appalachian area.  For this study, 96.7% of the sample reported their race/ethnicity as 
“white/Caucasian” and 3.3% reported “black/African American.”  The mean age of the sample 
was 48.2 years (SD = 11.1), with patients ranging from 19 to 80 years old.  The sample consisted 
of 89 females (58.9%) and 62 males (41.1%).  The education level of participants was as 
follows: 11th grade and below (29, 19.2%), high school graduate or GED (65, 43.0%), 
Associate’s degree or some college (30, 19.9%), and Bachelor’s degree or higher (17, 11.3%).        
Opioid Risk Evaluation  
Patients participating in the opioid risk evaluation typically were new chronic pain 
patients attempting to establish care at the Family Medicine clinic; however, any individual 
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attempting to or being considered for long term opioid treatment can be referred for an 
evaluation.  The resident physicians at the clinic are required by department policies to refer their 
patients and the attending physicians are expected to refer their patients, but may not follow this 
guideline unless they have a concern about the patient (e.g., psychological problem, substance 
abuse).  Additionally, patients presenting with obvious high risk indicators (e.g., active substance 
abuse or opioid misuse) may not be referred for an opioid risk evaluation and instead may be 
rejected for opioid consideration by the physician before beginning the evaluative process.  As 
previously described, the patient meets with a psychologist or psychology trainee for a clinical 
interview which addresses his/her pain triggers, goals for pain and function, impact of pain on 
functioning, pain treatment history, social and family history, and personal and familial 
substance abuse history.  After this interview, the trainee and supervisor thoroughly discuss the 
case and identify any potential problem areas based on information in the literature.  If a trainee 
was not involved, the licensed psychologist identifies problem areas independently.  These 
potential problem areas include: history of substance abuse, family history of substance abuse, 
psychopathology, alliance with provider, history of compliance, lifestyle stability, willingness to 
pursue pain management options other than opioids, and mental health problems.   
After discussing the patient, reviewing the patient’s medical record, and interpreting their 
self-report measures, a risk status is ascribed to the patient.  This risk status is based on the 
number and severity of each potential problem area, which then is interpreted into one of the 
following risk categories: low, low-moderate, moderate, moderate-high, or high, as previously 
described.  Certain factors may be weighted more heavily due to the abundance of research 
regarding the risk of opioid abuse and said factor.  For example, if a patient has an extensive 
history of substance abuse with numerous failed sobriety attempts or no sobriety attempts, this 
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patient likely would be considered high risk.  Other factors that likely indicate high risk include 
current substance abuse, and evidence of diversion or medication misuse/abuse.   
Next, a report is generated which outlines the presenting problem, medical/psychological 
history, current medications, history of pain problem, relevant psychosocial history, current 
status and functioning, mental status, standardized testing (i.e., McGill Pain Questionnaire, Pain 
Disability Index, Tampa Scale for Kinesiophobia, Beck Depression Inventory-II, Screener and 
Opioid Assessment for Patients), diagnostic impressions, and lastly the conclusions and 
recommendations.  The conclusions and recommendations section outlines the patients risk 
status for misuse of opioid pain medications, presents positive indicators and cautions, and 
specific treatment options that may be helpful for the patient, which may or may not include a 
recommendation for opioid analgesics.  This report is included in the patient’s medical record 
and is not considered a protected document as most psychiatry notes. The purpose is for this 
information to be accessible to the physicians managing the patient’s pain problem.  Because this 
report is not protected beyond the strict standard of access to the medical record system, the 
writer of the report will not include detailed information about potentially sensitive topics, such 
as sexual abuse.  Instead the writer may indicate that the patient experienced abuse, and report 
more specific information directly to the physician, if it seems necessary for treatment.  This 
safeguard is in place to protect the patient’s privacy and maintain confidentiality.    
Considering the prescribing of opioid analgesics, it is important to note that the West 
Virginia University Department of Family Medicine has policies in place which have evolved 
over the course of the past few years.  The requirement of opioid risk evaluations prior to 
prescribing was established in Fall 2010 and additional guidelines were added, including a check 
of the Board of Pharmacy for the patient, urine drug screens prior to prescribing and periodically 
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thereafter, and an approximate 30 day waiting period before physicians are allowed to prescribed 
analgesic narcotics to patients.  Of note, no other study has been conducted in a setting with this 
type of system-level protocol in place. Therefore, it is unclear how such a protocol may affect the 
outcome of this investigation; however, its impact may be such that there is a decrease of high 
risk patients continuing treatment in this setting due to the “transaction costs” (Coase, 1937; 
Rice, 1998; Stiles, Mick, & Wise, 2001).    
Self-Report Measures 
Demographic and general pain information questionnaire.  The demographic form is 
a self-report questionnaire consisting of approximately 30 items (see Appendix C).  It covers 
general demographic information, queries the respondent about number of times the patient has 
utilized the emergency department in the past year, tactics attempted to alleviate pain (e.g., yoga, 
physical therapy, medication) and the patients perceived degree of helpfulness, as well as 
caffeine, alcohol, nicotine, and other substance use.  Additionally, it includes items related to 
previous and current psychological symptoms (e.g., loss of energy, feeling nervous, hearing 
voices in your head).   
Short Form-McGill Pain Questionnaire.  The Short Form-McGill Pain Questionnaire 
(SF-MPQ) is a 15-item self-report questionnaire which utilizes a four-point scale (0 = none to 3 
= severe) requiring respondents to indicate the severity of various pain descriptors (e.g., 
throbbing, gnawing, splitting; Melzack, 1987; see Appendix D). It consists of 11 sensory words 
and 4 affective words. Patients also rate their present pain intensity on a 0–5 scale. Total score 
ranges from 0-45; however, this measure may be best utilized to understand the type, intensity, 
and affective nature of the pain as the total score does not provide quantitative cut-offs for 
interpretation.  
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Administration time for the SF-MPQ is short, the instrument is widely used, and there is 
good evidence of reliability and validity.  The SF-MPQ has good internal consistency reliability 
(r = 0.73-0.89; Burckhardt & Bjelle, 1994) and demonstrates strong concurrent validity with the 
MPQ total score (r = 0.67-0.87; Melzack, 1987).  The SF-MPQ also has demonstrated an 
appropriate level of overlap (r = .51 to .94) with other pain measurements (e.g., Long-Form 
McGill Pain Questionnaire, Present Pain Intensity, Visual Analogue Scale; Melzack, 1987).  
Test-retest reliability over one- to three-days apart ranged from 0.62 to 0.95 in samples of 
patients with musculoskeletal pain and rheumatic pain (Strand, Ljunggren, Bogen, Ask, & 
Johnsen, 2008).  The SF-MPQ is a good measure of pain quality and intensity and has 
demonstrated adequate reliability and validity for inclusion in the current study. Internal 
consistency in this study was acceptable for the SF-MPQ (α = .84).  
Pain Disability Index.  The Pain Disability Index (PDI) is a 7-item, self-report measure 
designed to assess the degree to which several aspects of the patient’s life presently are disrupted 
by persistent pain (Pollard, 1984; see Appendix E).  Respondents are asked to rate, on a 10-point 
scale (0 = no disability to 10 = total disability), the level of disability they experience due to 
persistent pain in various life activities (e.g., family and home responsibilities, recreational 
activities).  Total scores range from 0-70; higher scores indicate greater disability.   
The PDI has the following strengths: short administration time, assessment of disability 
level related to a broad range of life events, established norms for clinical (i.e., chronic pain) 
populations, and well-evidenced reliability and validity.  Internal consistency was good, 
Cronbach’s α = .86, within a chronic low back pain sample (Pollard, 1984).  Test-retest 
reliability over a one week interval was found to be good, ICC = .91 (Grönblad et al., 1993; Tait, 
Chibnall, & Krause, 1990). Additionally, Pollard (1984) found that using the PDI allowed 
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differentiation between patients with chronic low back pain who were categorized as highly or 
minimally disabled.  For the demonstrated ability to discriminate between those with high and 
low disability and the adequate reliability and validity, this instrument is of value for the present 
study.  Cronbach’s alpha for the PDI in the current study was .83.  
Pain Catastrophizing Scale.  The Pain Catastrophizing Scale (PCS) is a 13-item self-
report measure of thoughts and feelings patients may have when in pain (Sullivan, Bishop, & 
Pivik, 1995; see Appendix F).  Respondents rate the degree to which they experience various 
thoughts and feelings on a five-point Likert-type scale from not at all to all the time.  Examples 
of items include “I worry all the time about whether the pain will end” and “There’s nothing I 
can do to reduce the intensity of the pain.”  The PCS yields a total score (0-52) and three 
subscale scores assessing rumination, magnification and helplessness. Higher scores indicate 
more negative thoughts and feelings about pain.   
The PCS is relatively short, there are established norms for clinical (i.e., chronic pain) 
and nonclinical populations, and there is good evidence of reliability and validity.  The PCS has 
adequate to excellent internal consistency for both the total score (Cronbach’s α = .87) and 
subscales (rumination, α = .87; magnification, α = .66, and helplessness, α = .78; Sullivan et al., 
1995).  Test-retest reliability over a six-week period was found to be good by Sullivan et al., 
(1995), r = 0.75.  Studies by Osman et al., (1997 & 2000) found additional support for the three-
factor structure of the PCS and further evidence of reliability, as well as criterion-related, 
concurrent, and discriminant validity.  For its ease of use and well-evidenced reliability and 
validity, the PCS is a good measure of negative cognitions associated with chronic pain for the 
current study.  Internal consistency for the PCS in this study was acceptable (α = .94).  
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Tampa Scale for Kinesiophobia. The Tampa Scale for Kinesiophobia (TSK) is a 17-
item, self-report measure designed to assess the degree to which patient’s fear or worry about 
movement and activity (Miller, Kori, & Todd, 1991; see Appendix G).  Respondents are asked to 
rate, on a 4-point scale (1 = strongly disagree to 4 = strongly agree), the degree to which each 
statement represents their feelings.  Items include, “I’m afraid I might injure myself if I 
exercise,” and “People aren’t taking my medical condition seriously enough.”  Total scores range 
from 17-68; higher scores indicate greater fear of movement or activity. 
Administration time for the TSK is relatively short, there are established norms for 
clinical (i.e., chronic pain) and nonclinical populations, and good evidence of reliability and 
validity.  In a sample of adults with chronic back and/or neck pain, a Cronbach’s alpha of 0.84 
was observed, indicating a high level of internal consistency (French, France, Vigneau, French, 
& Evans, 2007).  Test-retest reliability of the total score has been established by Swinkels-
Meewisse, Swinkels, Verbeek, Vlaeyen, and Oostendorp (2003), r = 0.78.  Convergent and 
discriminant validity was found to be good when compared to other measures of fear-avoidance 
behavior and pain catastrophizing (French et al., 2007).  Additionally French and colleagues 
(2007) found additional support for the two-factor model originally found by Clark, Kori, and 
Brockel (1996) and later reaffirmed by Roelofs, Goubert, Peters, Vlaeyen, and Crombez (2004).  
For its ease of use and well-evidenced reliability and validity, the TSK is a good measure of fear 
and avoidance of movement and activity for the current study. Cronbach’s alpha for the TSK in 
the current investigation was .81.  
Screener and Opioid Assessment for Patients with Pain-Revised.  The Screener and 
Opioid Assessment for Patients with Pain-Revised (SOAPP-R) is a 24-item self-report measure 
utilized for screening risk potential for aberrant medication-related behavior among persons with 
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chronic pain (Butler, Fernandez, Benoit, Budman, & Jamison, 2008; see Appendix H).  
Respondents rate the frequency they experience symptoms and events related to opioid misuse 
on a five-point Likert-type scale from never to very often.  Examples of items include “How 
often do you have mood swings” and “How often have you counted pain pills to see how many 
are remaining.”  Total score ranges from 0-96, scores ≥18 indicates the patient is at risk for 
opioid misuse. 
The SOAPP-R is widely used to assess potential for opioid abuse, there are established 
norms for clinical (i.e., chronic pain) and nonclinical populations, and good evidence of 
reliability and validity.  In a sample of patients prescribed opioid medication for chronic 
noncancer pain, a Cronbach’s alpha of 0.88 was observed, indicating adequate internal 
consistency and excellent test-retest reliability over one week was demonstrated, r = .92 (Butler 
et al., 2008).  Convergent and discriminant validity was found to be good when compared to 
other measures of aberrant drug behavior and social desirability (Butler et al., 2008).  The 
SOAPP-R provides important information about the potential for opioid misuse and 
demonstrates good reliability and validity; as such it is a valuable measure for this investigation. 
Internal consistency for the SOAPP-R in the current study was acceptable (α = .90).  
Beck Depression Inventory-II. The Beck Depression Inventory-II (BDI-II) is a 21 item 
self-report questionnaire which utilizes a four-point scale (0 = minimal to 3 = severe) requiring 
respondents to indicate the severity of depressive symptoms (Beck, Steer, & Brown, 1996). The 
items on the BDI-II include questions relating to hopelessness, irritability, guilt, fatigue, weight 
loss, and lack of interest in sex. Total score ranges from 0 to 63, with cutoff scores indicating 
minimal, mild, moderate, and severe depression.  
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The BDI-II is widely used both clinically and in research, there are established norms for 
clinical (i.e., chronic pain) and nonclinical populations, and good evidence of reliability and 
validity.  Both high internal consistency (α = .92) and high convergent validity have been 
established for the BDI-II based on Pearson correlations between the BDI-II and the depression 
scale of the SCL-90-R (r =.89; Steer, Clark, & Beck, 1999).  Additionally, in a sample of chronic 
pain patients, internal consistency remained high (α = .92), and results supported a singular 
second-order latent construct with three-factor subscales (i.e., Negative Attitude, Performance 
Difficulty, and Somatic Elements; Harris & D’Eon, 2008).  Test-retest reliability over a one-
week period was found to be good by Sprinkle et al. (2002), r = 0.96, which is similar to that 
found by Beck, Steer, and Brown (1996), r = .93.  Because it has well-evidenced reliability and 
validity for both chronic pain and nonclinical samples, the BDI-II is a good measure of 
depression for the current study.  Cronbach’s alpha for the BDI-II in this study was .91.  The 
BDI-II is not displayed in the appendices due to its copyrighted status. 
Electronic Medical Record Review 
Electronic medical records were available for all of the participants of the study through 
the West Virginia University Department of Family Medicine clinic.  Information gathered from 
the electronic medical record was immediately entered into a database to assure complete 
abstraction across participants.  Several variables were collected including, whether the patient 
was prescribed an opioid at the first appointment following the opioid risk evaluation, the 
prescribing physician’s training level and sex, patient’s primary pain condition, mental health 
diagnoses, history of substance abuse, family history of substance abuse, history of abuse, 
employment status, smoking status, education level, evaluator training level, Board of Pharmacy 
review, urine drug screen, as well as the patient’s sex, age, ethnicity/race, and scores on the 
PREDICTING OPIOID PRESCRIBING BEHAVIOR      
     
30 
SOAPP-R, PCS, PCI, TSK, and BDI-II.  This chart review process provided a comprehensive 
and standardized measure of potential factors related to being prescribed an opioid.  
Access to electronic medical records was approved by the West Virginia University 
Department of Family Medicine dean and the appropriate faculty and administrators.  Electronic 
medical record reviews were conducted by Alison Vargovich, under the supervision of 
collaborators at the Department of Family Medicine.  Chart abstraction reliability was assessed 
via abstraction comparison for 10% of the cases across 158 participants with reliability checks 
conducted every 20 participants by Jeannie Sperry, Ph.D., as she was the Family Medicine 
supervisor at the time.  Reliability was excellent across the data collection window; there were 
no discrepancies in the recorded outcome variables, and minimal discrepancies in all other 
variables collected across patients.  More specifically, for all participants included in the 
reliability checks, 240 out of 260 variable cases, or 90.2%, were congruent between the dataset 
and reliability check.  There were 26 out of 266 variable cases with discrepancies (9.8%), but 
after closer inspection only 4 out of those 26 variable cases, or 15.4%, required a modification to 
the dataset.  Prior to data collection, Alison Vargovich and Jeannie Sperry, Ph.D. were trained on 
the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy and Security 
Rules and had current ethics training and Collaborative Institutional Training Initiative (CITI) 
program certification for work with human subjects.   
Results 
 All Statistical analyses were performed using PASW Statistics 21.0.0.0 (IBM SPSS, 
Chicago, IL).  Variables first were examined to ensure there were no out-of-range values that 
were theoretically impossible based on the structure of the variable (e.g., possible questionnaire 
responses), and any issues addressed. 
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 As suggested by Menard (2010), preliminary analysis of the data was performed to check 
the assumptions of logistic regression with respect to the selected predictors of the study.  
Univariate outliers were detected by considering histograms and box plots for each variable.  
There were 18 individual data points detected as potential outliers across all of the variables.  
These outliers were further evaluated by comparing the mean to the 5% trimmed mean to 
determine the influence the potential outliers were having on the data (Pallant, 2010).  These 
outliers were not determined to be significantly influencing the mean and were included in the 
dataset.  Outliers for dichotomous variables were examined through frequencies to determine if 
any violated the 90%-10% split between groups; no variables violated this guideline (Howell, 
2010).  Multivariate outliers were screened by checking the data for participant leverage values 
greater than 2k/N, where k equals the number of predictor variables (Tabachnick & Fidell, 2007); 
no variables violated the multivariate outlier guidelines.   
All predictor variables were subjected to linear regression analysis to evaluate 
multicollinearity (Menard, 2010).  Multicollinearity among predictors in logistic regression 
creates problems for the validity of the model for the investigation.  In particular, it affects the 
validity of the statistical tests of the regression coefficients by inflating their standard errors 
(Garson, 2010).  The results of the analysis showed the data did not violate the multicollinearity 
assumption.  The collinearity statistics, specifically tolerance values and the variance inflation 
factor, were examined.  None of the variables were below the recommended guideline of .10 for 
tolerance or above 10 for the variance inflation factor, suggesting that there were no problems 
with multicollinearity among the variables (Field, 2005; Pallant, 2010).  See Table 3 for 
collinearity statistics.  Additionally, a bivariate correlational analysis was conducted to determine 
high correlations among variables (≥ .80; Tabachnick & Fidell, 2007).  The variables with the 
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highest correlation were the total score for the SOAPP-R and BDI-II, r = .65, p < .001; and no 
variables met or exceeded the suggested guideline.  See Table 4 for bivariate correlations for 
questionnaires.      
To address missing data, multiple imputation (MI) was utilized in order to reduce errors, 
maintain statistical power, and retain the cases in the dataset (Osborne, 2013). The MI statistical 
technique has been demonstrated to be superior to mean substitution, listwise deletion, and single 
imputation and results in greater generalizability and replicability as it explicitly models the 
missingness and gives the researcher confidence intervals for estimates rather than trusting to a 
single imputation (Schafer, 1999; Schafer & Graham, 2002).  The MI method involves three 
steps, imputation, analysis, and pooling.  First, the missing entries of the incomplete dataset are 
“filled in” or “imputed” with plausible values based on the distribution of the data derived from a 
combination of Bayesian theory and Monte Carlo technique.  These plausible values are imputed 
into a designated number of datasets determined by the researcher.  The suggested number is 
between 5 and 20 (Schafer, 1999; Schafer & Graham, 2002), but for these analyses it was 
determined that 10 imputed datasets would be sufficient due to the relatively small amount of 
missing values.  This first step results in 10 imputed datasets with plausible values replacing the 
missing items.  The second step, analysis, refers to the planned analyses that are conducted 
utilizing all of the imputed datasets, which results in the final step, pooling.  The output for the 
analyses includes statistics based on each imputed dataset, which is then combined and analyzed 
to provide “pooled” statistical output.     
In order to utilize the MI method, it is assumed the missing data are random; however, 
while it is preferred to be missing at random, the MI method is resilient to various types of 
missingness (Little & Rubin, 2002).  Additionally, to utilize the MI method effectively, it is 
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important to understand the total percentage of missing items and the percentage missing within 
a variable; however, the number missing within each case is irrelevant to the analyses as these 
values can be imputed accurately providing there is sufficient data within the variable (Schafer, 
1999; Schafer & Graham, 2002; Tabachnick & Fidell, 2012).  Due to the rigorous nature of the 
record review, there were minimal missing data in the variables collected from the patient’s 
medical record (1.7%); however, there were missing data among the self-report measures, which 
is what the multiple imputation was utilized to address.  In the current study, missing data were 
analyzed for patterns through the multiple imputation analyze patterns feature of SPSS to 
determine missingness.  There were no significant patterns identified and it was determined that 
the missing values were missing at random.  Further assessment of the missing values within the 
self-report measures revealed 5.6% missing across all of the participants in the form of items on 
the questionnaires. Additionally, there was <10% missing within each measure item, which is the 
suggested guideline (Bennett, 2001); however, Tabachnick and Fidell (2012) indicated that the 
missing data mechanisms and the missing data patterns likely have greater impact on research 
results than the proportion of missing data.  See Table 5 for the percentage of missing items for 
each measure.     
Primary Data Analyses 
Research Question 1 
Were patients who were prescribed opioids at the first appointment following the 
opioid risk evaluation different from those who were not prescribed an opioid? Descriptive 
statistics (e.g., means and standard deviations) for relevant dependent and independent variables, 
across the entire study sample are reported in Tables 6 and 7.  Additional information about 
differences in demographic and psychosocial variables by opioid prescribing group is in Tables 8 
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and 9.  Chronic pain diagnoses and mental health problems across groups are presented in Table 
10. Across groups (i.e., prescribed an opioid, not prescribed an opioid) patients did not differ 
significantly in demographic variables, specifically age, t (149) = -.80, p = .43, sex, (1, N = 
151) = .05, p = .83, phi = .03, or ethnicity/race (i.e., black and white), (1, N = 151) = 1.70, p = 
.19, phi = -.14.   
Further analyses, t-tests for continuous variables and chi-square tests for independence 
(with Yates Continuity Correction) for categorical variables, were conducted to investigate 
possible group differences across several variables, as shown in Tables 8 and 9.  Variables 
assessed included the following: employment, relationship, and smoking status, abuse history, 
substance abuse, family substance abuse, education, pain diagnoses, mental health diagnoses, 
pain rating at the time of the appointment, duration of chronic pain, number of times married, 
number of children, as well as total scores for self-reported pain severity (MPQSF), pain 
catastrophizing (PCS), misuse or diversion behaviors (SOAPP-R), depression symptoms (BDI-
II), pain disability (PDI), and fear of movement (TSK). .  Patients who were more likely to be 
prescribed an opioid included those who were married or with a long-term partner and those 
patients who reported higher level of education. Patients who were less likely to be prescribed an 
opioid included those reporting some form of abuse, a history of substance abuse, a higher pain 
rating at the time of the evaluation, as well as patients with higher scores on the PCS, SOAPP-R, 
and BDI-II.   
Research Question 2 
 Did the patient’s opioid risk status affect whether a physician prescribed an opioid 
at the first appointment following the evaluation?  The dependent variable, opioid 
prescribing, was constructed as a “yes/no” dichotomous indicator of whether or not a patient was 
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prescribed an opioid following an opioid risk evaluation.  Patients prescribed an opioid at the 
first appointment following the opioid risk evaluation were coded as YES (1) and patients not 
prescribed an opioid or did not return following the opioid risk evaluation were coded as NO (0).  
The dependent variable, risk status, was coded with High = 1, Moderate and Moderate-High = 2, 
and Low and Low-Moderate = 3.  See Table 11 for the number of patients in each risk category 
by opioid prescribing group.  
 In order to examine the predictive association between opioid risk status (i.e., low/low-
moderate, moderate/moderate-high, high) and opioid prescription decision (i.e., prescribed, not 
prescribed), a binary logistic regression was conducted.  The overall model was statistically 
significant, (1, N = 151) = 37.10, p < .001, indicating that the model was able to distinguish 
between patients who were prescribed an opioid and those who were not.  The model as a whole 
explained between 21.8% (Cox and Snell R square) and 29.3% (Nagelkerke R squared) of the 
variance in opioid prescribing, and correctly classified 72.2% of cases.  The Wald statistic 
indicated that the risk status variable significantly predicted opioid prescribing.  The 
unstandardized regression coefficient is positive which indicates a positive relation with the 
probability of "success" (i.e., when risk status decreases probability of being prescribed an opioid 
increases).  Additionally, when the probability of being prescribed an opioid is more than the 
probability not being prescribed an opioid, then the odds ratio will be greater than 1, as it is in 
the current analysis.  Therefore, the odds of being prescribed an opioid increased 4.22 times for 
each level decrease in risk status.  See Table 12 for more information. 
Research Question 3 
What other variables influenced physician opioid prescribing behavior?  Next, a 
series of univariate logistic regressions (i.e., each analysis included one predictor variable) was 
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utilized to examine potentially significant variables in predicting physician opioid prescribing to 
determine which factors should be included in the final model (Agresti, 2007).  Based on the 
literature, there were 21 factors independently reviewed and considered for inclusion in analyses.  
These variables were: patient’s sex, patient’s age, substance abuse history, familial substance 
abuse history, mental health diagnoses, current smoking status, employment status, history of 
abuse, relationship status, education, pain diagnoses, Board of Pharmacy review, urine drug 
screen, physician training level, physician sex, as well as total scores on the SFMPQ, PCS, PDI, 
SOAPP-R, TSK, and BDI-II.  The Board of Pharmacy review and urine drug screen variables 
were excluded from analyses as both variables had inadequate data for inclusion in analyses with 
the urine drug screen missing in 69.5% of the sample and the Board of Pharmacy review missing 
in 79.5% of the sample.  This information was missing as it was not consistently reported in the 
patient’s electronic medical record, which may be due to the patient not undergoing a urine drug 
screen or Board of Pharmacy review, or physicians not reporting this information in the medical 
record, as it only recently was required by West Virginia state law in July 2012 (West Virginia 
State Code, 2012).  All 19 other variables were included in this stage of analysis.  The variables 
that made a unique statistically significant contribution to the model at the p < .05 level were 
substance abuse history, history of abuse, relationship status, education, and total scores on the 
SOAPP-R, PCS, and BDI-II.  Due to the number of variables significant at the 0.05 level, values 
at the 0.25 level were not considered as there would not be enough power to adequately assess 
these variables in further analyses (Bendel & Afifi, 1977; Mickey & Greenland, 1989).  See 
Table 13 and 14 for pertinent information regarding these variables.  
Based on the significant factors discovered in the series of univariate binary logistic 
regressions, a multivariate logistic regression was conducted.  The variables of substance abuse 
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history, history of physical abuse, relationship status, education, and total scores on the SOAPP-
R, PCS, and BDI-II were entered as the independent variables, and whether the physician 
prescribed an opioid at the first appointment following the opioid risk evaluation as the 
dependent variable.  Risk status was not included in this analysis in order to determine the 
contribution of these other variables to the predictive model.  After examining the overall model 
and variable statistics, the variables of history of abuse, education, and total scores on the 
SOAPP-R, PCS, and BDI-II were removed from the analyses as they did not account for a 
significant amount of the variance; however, substance abuse history remained statistically 
significant.  When removing substance abuse history from the analyses, the overall model 
remained significant; however, none of the predictor variables were significant.  Therefore, the 
final model included substance abuse history and risk status, but no other predictor variables.  
See Table 15 for additional information on the variables and model. 
Research Question 4  
How did the inclusion of opioid risk status and other significant variables, as 
determined in research question 3, affect whether a physician prescribes an opioid at the 
first appointment following the opioid risk evaluation?  To examine the unique contribution 
of risk status in the prediction of opioid prescribing, a hierarchical logistic regression analysis 
was conducted.  In step one, opioid prescribing was the dependent variable, and substance abuse 
history was included as a control variable.  Due to the lack of significance within the binary 
logistic regressions for age and sex, these variables were not included as control variables.  In 
step two, the risk status variable was entered into the equation.   
 The results of step one indicated that the model was statistically significant (2, N = 
151) = 20.44, p < .001, with substance abuse history being statistically significant at the p < .001 
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level.  In step two, risk status was entered into the regression equation.  The overall model was 
statistically significant, (2, N = 151) = 39.61, p < .001, indicating that the model was able to 
distinguish between patients who were prescribed an opioid and patients who were not.  The 
model as a whole explained between 23.1% (Cox and Snell R square) and 31.1% (Nagelkerke R 
squared) of the variance in opioid prescribing, and correctly classified 70.9% of cases.  This 
additional step was significant,  (1, N = 151) = 19.17, p < .001, indicating that the added risk 
status variable significantly improved the model.  Wald statistics indicate that only the risk status 
variable was significant in the final model (p < .001), and substance abuse history was no longer 
significant (p = .11).  The odds of being prescribed an opioid increased 3.40 times for each level 
decrease in risk status. See Table 16 for additional information. 
The inclusion of substance abuse history in the model minimally reduces the percentage 
of correctly classified patients from 72.2% to 70.9%.  Additionally, when the analysis was 
conducted with only substance abuse history as the predictor variable, the model was significant, 
 (1, N = 151) = 20.44, p < .001, substance abuse history was significant at the p < .001 level, 
and the model correctly classified 69.5% of the patients. It appears that substance abuse history 
parallels the predictive utility of risk status, when included independently. While these variables 
both significantly predict opioid prescribing independently, it was decided that the final model 
only should include risk status as it was the variable of interest; it remained significant when 
included with substance abuse history, and substance abuse history did not improve the overall 
model.  See Table 12 for the final model.  
The overall predictive utility of the final model can be found using the Receiver 
Operating Characteristic (ROC) curve analysis (Metz, 1978; Zweig & Campbell, 1993) with 
opioid prescribing being the state variable and the predicted probabilities as the test variable.  
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This test demonstrates how well the model classifies individuals and selects a “cut-off” point to 
maximize sensitivity and specificity.  To interpret the area under the curve (AUC) statistic, an 
AUC of 1 represents a perfect classification and an AUC of 0.5 represents the same accuracy as 
chance.  A general guide is that fair-to-excellent accuracy is achieved when AUC ≥ 0.7 (i.e., .90-
1 = excellent, .80-.90 = good, .70-.80 = fair, .60-.70 = poor, and .50-.60 = inclusive/little to no 
utility; Hanley & McNeil, 1982; Zou et al., 2003).  The ROC curve analysis showed that the area 
under the ROC curve was .76 (76.3%; CI = 69-84%).  The model is significantly better than 
chance, in terms of classifying whether or not a patient was prescribed an opioid, p < .001.   
Exploratory Analyses 
An area of concern was the differences between residents’ and attending physicians’ use 
of the risk status information.  Due to the selection bias which exists when referring patients (i.e., 
residents are required, attending physicians are strongly encouraged), it was unclear how 
attending physicians may refer patients and if they would utilize the opioid risk evaluation in 
their prescribing decision.  Based on the sample of 151 patients, 49 were referred by attending 
physicians and 102 by resident physicians. (See Tables 2 and 17 for additional information about 
referrals by physician training.)  The 49 referrals came from 13 different attending physicians 
and the 102 referrals came from 27 different resident physicians.  These numbers are uneven, 
though there are relatively equivalent numbers of resident and attending physicians on staff (i.e., 
~20 of each).  A chi-square test for independence (with Yates Continuity Correction) was 
conducted to determine if there was an association between risk status and physician training 
level.  This relationship was not significant, (2, N = 151) = .69, p = .71.  Next, a binary 
logistic regression was conducted with opioid prescribing as the outcome variable and physician 
training level as the predictor variable.  Neither the overall model,  (1, N = 151) = 1.49, p = 
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.22, nor the Wald statistic, Wald = 1.47, p = .23, were statistically significant.  This outcome 
suggests that the model was not able to distinguish between patients who were prescribed an 
opioid and patients who were not, based on physician training level alone.  
Additionally, a secondary concern involved the different levels of training within the 
psychology team (i.e., graduate students, predoctoral interns, postdoctoral fellows, and licensed 
psychologists) assigning the risk status and the potential for bias when assigning.  In order to 
examine this concern, a chi-square test for independence (with Yates Continuity Correction) was 
conducted between opioid risk status (i.e., low/low-moderate, moderate/moderate-high, high) 
and evaluator training level (i.e., graduate students, predoctoral interns, postdoctoral fellows, 
licensed psychologists).  There was no significant association between opioid risk status and 
evaluator training level,  (6, N = 151) = 10.31, p = .12, phi = .26.  See Table 1 for frequencies 
and percentages of assigned risk status by evaluator training level.  Additional analyses and 
examination are necessary to fully understand the role of the evaluator and the influence it has on 
opioid risk status and prescribing; however, it does not appear to be an issue within this sample.  
Discussion 
 Few studies have addressed opioid prescribing behaviors beyond patient demographic 
attributes.  Moreover, little research has addressed how psychological evaluation, and assignment 
of risk status, may contribute to decisions by physicians in prescribing for the treatment of 
chronic pain.  The current study has several interesting findings regarding opioid prescribing and 
patient characteristics.  Patients prescribed an opioid were more likely to be married or with a 
long term partner and have a higher level of education.  Patients not prescribed an opioid were 
more likely to report a higher pain rating at the time of the evaluation, a history of abuse or 
substance abuse, or have higher total scores for pain catastrophizing (PCS), misuse or diversion 
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behaviors (SOAPP-R), and depression symptoms (BDI-II).  Additionally, the best predictors of 
opioid prescribing were substance abuse and opioid risk status, with patients with no history of 
substance abuse and lower risk status being more likely to be prescribed an opioid.  The finding 
that substance abuse history is related to opioid prescribing corroborates previous study findings 
(e.g., Pergolizzi, 2012; Turk, Swanson, & Gatchel, 2008); however, the influence of opioid risk 
status on opioid prescribing is an interesting and important finding.  Interestingly, age, sex, and 
ethnicity/race were not significant predictors of opioid prescribing, suggesting that providing 
physicians with additional information about their chronic pain patient’s potential for opioid 
abuse may act to reduce prescribing bias based on demographic factors as found in previous 
studies.   
Overall Findings   
 The first aim of the current investigation was to explore the differences between patients 
prescribed or not prescribed opioids.  Patients prescribed and not prescribed an opioid were not 
significantly different based on age, sex, race, employment status or smoking status, mental 
health diagnoses, pain diagnoses, family history of substance abuse, number of children or times 
married, duration of chronic pain, or total scores on measures of pain severity (MPQSF), pain 
disability (PDI), and fear of movement (TSK).  The lack of demographic differences between 
these two groups is alone an interesting finding.  Previous research has demonstrated that nurses 
and physicians often are influenced by age, sex, and race when making prescribing decisions 
(Burgess et al., 2008; Hirsh, George, & Robinson, 2009; Olsen, Daumit, & Ford, 2006; Pletcher, 
Kertesz, Kohn, & Gonzales, 2008; Tamayo-Sarver, Hinze, Cydulka, & Baker, 2003; Weisse, 
Sorum, Sanders, & Syat, 2001).  The current study may not have detected differences in these 
demographic factors due to having a smaller sample size (N = 151) than other similar 
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investigations (e.g., N = 382 in Burgess et al., 2008), especially in regard to race.  Interestingly, 
only one of the studies just mentioned utilized patients presenting to a primary care office (i.e., 
Weisse, Sorum, Sanders, & Syat, 2001) with a sample size of 111, and this investigation did not 
find any significant differences in prescribing based on patient sex or ethnicity/race, but did find 
a significant interaction between physician sex and gender/racial and ethnicity cues.  The other 
investigations just mentioned were conducted utilizing patients presenting to emergency 
departments for care (i.e., Pletcher, Kertesz, Kohn, & Gonzales, 2008; Tamayo-Sarver, Hinze, 
Cydulka, & Baker, 2003) or did not occur with “real” patients and instead utilized virtual 
humans or had physicians read paper vignettes about patients (i.e., Burgess et al., 2008; Hirsh, 
George, & Robinson, 2009).  Lastly, Olsen, Daumit, and Ford (2006) based their findings on the 
National Ambulatory Medical Care Survey, which includes both ambulatory and outpatient 
departments.  The lack of significance between age, sex, and ethnicity/race found in this 
investigation and the study conducted by Weisse et al. (2001) suggests that there may be 
something unique about Family Medicine patient populations; however, additional analyses are 
necessary to determine if there were any interaction effects within the current investigation.   
The groups differed based on their pain rating at the time of the opioid risk evaluation, 
history of abuse or substance abuse, relationship status, level of education, and scores on the 
PCS, SOAPP-R, and BDI-II.  Patients not prescribed an opioid were more likely to have higher 
pain ratings at the time of the evaluation, report a history of abuse, be single or divorced, and 
have higher scores on the PCS, SOAPP-R, and BDI-II.  These results are not surprising as all of 
these variables are considered when deciding risk status, and have associations with opioid or 
substance abuse in the literature.  A patient presenting to clinic with these characteristics (i.e., 
anxious/depressed, exhibiting misuse or diversion behaviors) likely is more complicated than a 
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patient without these particular problems, and may signal a higher risk to the evaluator or 
physician.  It is difficult to determine how the patient interacted with the psychology team or 
physician, but research findings suggest that patients with a more complicated presentation are 
more difficult to treat (Matthias et al., 2010), and these characteristics may be the most apparent, 
as compared to other variables that were examined.  
 The second aim of this study was to examine the influence of opioid risk status on opioid 
prescribing.  Patient care has improved and healthcare costs have been reduced with the 
inclusion of interdisciplinary integrated care (Blumenthal et al., 2005; van Orden, Hoffman, 
Haffmans, Spinhoven, & Hoencamp, 2009); however, it was unclear if physicians incorporated 
the recommendations from other professionals into their decision making process and how it 
may affect their treatment of chronic pain patients.  The results of this aim suggest that 
physicians integrate the recommendations of the psychological team into their decision making 
process when prescribing opioid analgesics.  It is possible that having a variety of factors 
consolidated into a singular risk status may be beneficial to physicians in understanding their 
patient’s opioid abuse potential as many physicians lack training in discerning opioid abuse and 
diversion (Matthias et al., 2010; Richeimer, 2005), and having to consider multiple risk factors, 
instead of a singular risk status may be overwhelming, time consuming, and unhelpful.   
 The third aim was to determine if any other factors outlined in the literature were 
predictive of opioid prescribing.  After identifying risk status as a significant predictor, it was 
important to further evaluate other variables influence on opioid prescribing.  Several variables 
significantly predicted opioid prescribing as expected based on the literature, specifically history 
of substance abuse, level of education, relationship status, and scores on the SOAPP-R, BDI-II, 
and PCS.  These variables have been identified as factors related to potential opioid abuse and 
PREDICTING OPIOID PRESCRIBING BEHAVIOR      
     
44 
therefore were expected to be significant predictors (Breitbart et al., 1997; Chou, 2009; Passik, 
Messina, Golsorkhi, & Xie, 2010; Pergolizzi et al., 2012; Portenoy, 1996; Rice et al., 2012; Turk, 
Swanson, & Gatchel, 2008; Weaver & Schnoll, 2002; Ziegler, 2005).  Interestingly, patients’ 
history of abuse also significantly predicted opioid prescribing, with patients reporting a history 
of physical or sexual abuse being less likely to be prescribed an opioid.  History of preadolescent 
sexual abuse has been identified as a potential risk factor for substance abuse (Kendler, Bulik, 
Silberg, Hettema, Myers, & Prescott, 2000; Mullen, Martin, Anderson, Romans, & Herbison, 
1993), but has not been associated with opioid prescribing or specifically for opioid abuse.  For 
this study, the patients’ history of abuse included both sexual and physical abuse identified by 
the patient, demonstrating the potential influence of this history on opioid prescribing.  It is 
unclear whether these patients should or should not be prescribed an opioid; however, a history 
of abuse has been associated with mental health and substance abuse problems (Beitchman et al., 
1992; Mullen, Martin, Anderson, Romans, & Herbison, 1996; Nikulina, Widom, & Brzustowicz, 
2012), as well as a number of medical problems, including obesity, chronic headaches, chronic 
pelvic pain, somatization, and certain surgical procedures (e.g., hysterectomy; Felitti, 1991; Irish, 
Kobayashi, & Delahanty, 2010; Longstreth, 1994; Springs & Friedrich, 1992).  When 
considering the potential psychological comorbidities associated with abuse, it is possible that 
patients presenting with a history of abuse also had additional problems.  This presentation may 
result in the psychology team increasing the patient’s risk status and recommending alternative 
treatments prior to prescribing opioids.      
 The final aim was to utilize the significant factors to develop a predictive model.  
Unexpectedly, while many factors were significant predictors independently, when added to the 
full model, these factors no longer were significant.  Results of multivariate logistic regression 
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analysis demonstrated that the predictor variables likely share variance with the risk status 
assigned to each patient as many of these variables were utilized to determine said status; 
however, substance abuse history remained significant until included with risk status.  Therefore, 
the best predictor of opioid prescribing appears to be the risk status assigned by the 
psychological team, as well as substance abuse history, when considered independently; 
however, when included alone, risk status demonstrated better model fit than when included with 
substance abuse or substance abuse on its own.  These results suggest the effectiveness in 
providing supplemental information to physicians to aid in opioid prescribing decisions, and may 
act to reduce prescribing bias based on demographic factors (i.e., age, ethnicity/race, gender).  
Physicians have reported having less training and confidence in treating chronic pain and 
identifying opioid abuse and diversion (Glajchen, 2001; Matthias, 2010; Richeimer, 2005).  By 
providing physicians with a condensed version of the various risk factors through the singular 
risk status, they are able to more easily utilize evidence-based factors in their decision-making 
process, potentially reduce prescribing bias, and possibly avoiding conflict with their patients.   
Exploratory Analyses 
 Selection bias was thought to be a potential area of concern due to the policy related to 
referrals to the psychology team.  The WVU Family Medicine protocol requires resident 
physicians to refer all patients requesting or being considered for long-term opioid therapy; 
however, attending physicians are strongly encouraged, but not required.  While there were more 
referrals from resident physicians, there was no significant difference in opioid prescribing based 
on physician training level.  Additionally, after examining the crosstabulations between 
physician training level and risk status, the outcome of the evaluations for the referred patients 
was equivalent across risk status and physician training level, with no significant differences.  
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This finding suggests that when attending physicians refer patients for an evaluation the patients 
likely are not all psychosocially complex, as previously assumed.  The attending physicians refer 
an array of patients, or at least that is how it appears post opioid risk status.  See Table 17 for this 
information.   
 A secondary concern involved the different levels of training within the psychology team 
(i.e., graduate students, predoctoral interns, postdoctoral fellows, and licensed psychologists) 
assigning the risk status and the potential for bias when assigning.  It is possible that there is 
variability in how the evaluators’ assigned risk status as there is an element of clinical judgment 
inherent in each evaluation; however, there was no significant difference between opioid risk 
status and evaluator training level.  This finding suggests that within the study sample, evaluators 
from the four training levels assigned risk statuses in relatively equivalent numbers.  
Limitations and Strengths 
 Due to the retrospective design of the current investigation, there was little control over 
what was asked of the patients and what was included in the opioid risk evaluation.  While there 
was relative consistency across the format of the evaluations, some information had to be 
extrapolated from the patient’s medical record.  Unfortunately, some patients neglected to fully 
complete questionnaires resulting in missing data, which could not be recovered.  In addition, the 
information about opioid prescribing was based on the decision made at the next appointment 
following the opioid risk evaluation, and does not account for any changes, which may have 
occurred, following that appointment or other classes of medications prescribed.  Lastly, due to 
insufficient data, the information about patients’ Board of Pharmacy review and urine drug 
screens were unable to be analyzed.  It seemed that the majority of patients in this sample did not 
have the Board of Pharmacy review noted in their medical record, though it seemed to increase 
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in the evaluations conducted following July 2012, which coincides with new guidelines for 
reporting (West Virginia Code, 2012).  In regard to the urine drug screen, many patients did not 
have an initial screen in their records, and few patients had any follow-up screens.  Inclusion of 
this information may have modified the results; however, due to the lack of information in the 
medical record, it may be that physicians were not utilizing this information when prescribing. 
 Unfortunately, there was little information about the opioid prescribing practices of 
physicians in the clinic prior to the institution of the opioid risk evaluations in late 2010.  It could 
be assumed that the opioid prescribing practices were likely less stringent as it was a different 
socio-political climate and opioid abuse was not as evident at that time.  Only in the past four 
years has the focus shifted to prescribing less and more carefully and creating more stringent 
guidelines for chronic opioid therapy through the recommendation of major pain associations 
(i.e., Neuropathic Pain Special Interest Group of the International Association for the Study of 
Pain; European Federation of Neurological Societies Task Force; Attal et al., 2010; Dworkin et 
al., 2010).  Therefore, physicians may have been more lenient with prescribing; however, there is 
not definitive information available to determine if this assumption is accurate or to determine 
what was predictive of opioid prescribing at that time.       
 The WVU Department of Family Medicine psychology team has a specific format for 
opioid risk evaluations based upon the current research available regarding opioid abuse and 
misuse; however, the final decision of assigning a risk status is decided utilizing a variety of 
information, as well as clinician judgment.  It is unclear how each clinician may be utilizing the 
information or which information is weighted more heavily when assigning risk status.  As a 
result, there is an inherent amount of variation within the opioid risk evaluations.    
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 Information from the physicians’ perspective regarding what he or she consciously 
considers when prescribing opioids would have been a helpful addition to the current data.  By 
understanding what the physician considers and comparing it to the current information, 
potential discrepancies could have been identified.  Additionally, it would be interesting to 
examine how heavily the physicians weighed various aspects of a patient’s presentation when 
prescribing, especially the opioid risk status.  Unfortunately, due to the nature of the current 
investigation, obtaining information from physicians would have been difficult and tainted by the 
retrospective design.  Some resident physicians have graduated from the program making them 
unavailable for questioning and unless the physicians were asked to evaluate cases on a patient-
by-patient basis it may lead to overgeneralizations or inaccurate self-critiques on their 
prescribing behaviors.     
Using patients at a family medicine clinic was a particular strength of this study; 
however, due to the ethnic/racial makeup of West Virginia, lack of diversity was a limitation.  
The current study would benefit from the inclusion of different races and ethnicities as the 
sample was 96.7% white and 3.3% black.  This limitation is consistent with the ethnic/racial 
profile of West Virginia (i.e., 94% Caucasian, 6% Other; U.S. Census Bureau, 2012), and should 
be addressed in future research.  
Future Research 
 The current project is the first known study of the influence of interdisciplinary 
recommendations on opioid prescribing.  With the growing emphasis on patient-centered care 
and interdisciplinary treatment, future work in this same area likely would improve professional 
interactions and team based approaches to treating complicated chronic pain patients.  One future 
direction of research might include designing a prospective longitudinal study that includes 
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qualitative information, specifically the physicians’ perspective when prescribing to determine 
which factors are considered and to what degree when making difficult prescribing decisions.  
Additionally, certain variables, which likely are influential in prescribing (i.e., Board of 
Pharmacy review, urine drug screen), often were not mentioned or not completed for patients 
making it difficult to determine if physicians utilized this information when prescribing.  In 
2012, West Virginia introduced a new law requiring the inclusion of this information in medical 
records for patients prescribed long term opioid medication (West Virginia Code, 2012).  This 
information should be included in future research to determine each variables predictive value in 
opioid prescribing, especially as it relates to risk status.   
 Other future work in this area may further examine the opioid risk evaluations to create a 
more consolidated approach and remove some of the inherent variation due to clinician 
judgment.  By deconstructing the evaluation, clinicians may be able to create a screener to 
determine which patients can be assessed through a brief evaluation instead of the lengthy full 
version.  This assessment of the evaluation material also may help to focus the opioid risk 
evaluations on the factors that seem to be most indicative of opioid misuse and abuse.  
Additionally, inclusion of feedback from physicians that specifies which information they are 
likely to attend to when prescribing may allow clinicians to create a shorter, more concise report 
for physician use.  Lastly, it is necessary to determine the accuracy of the opioid risk status 
through future follow-up with patients.  This information could be determined through Board of 
Pharmacy reviews, urine drug screens, and brief follow-up screenings with patients.  This 
information may prove difficult to obtain as some patients may choose to receive care elsewhere; 
however, it could be beneficial in understanding the static and dynamic risk factors over time.  
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After better understanding physician perspectives and the evaluation itself, a cost 
analyses would be a viable next step to better understand the impact on the larger healthcare 
system.  Previous research has shown that integrated care reduces treatment time, and results in 
fewer appointments and lower costs than traditional patient referral to offsite mental health 
centers (van Orden et al., 2009); however, it is unclear what impact these evaluations may have 
on costs associated with the treatment of chronic pain.  By better understanding the potential 
influence on costs, the feasibility of utilizing risk evaluations could be assessed.        
Conclusions 
The aims of this study were to: (a) explore the differences between patients prescribed or 
not prescribed opioids, (b) examine the influence of opioid risk status on opioid prescribing, (c) 
determine if any other factors outlined in the literature were predictive of opioid prescribing, and 
(d) utilize these factors to develop a predictive model.  To achieve these goals, electronic 
medical record reviews were conducted on 151 chronic pain patients seeking long term opioid 
therapy.  Using a series of univariate logistic regressions, several factors were identified as being 
significantly predictive of opioid prescribing; however, only two variables remained significant 
when included in the full model, substance abuse and risk status.   
 With the current socio-political agenda in regard to healthcare, (i.e., focus on reducing 
opioid abuse and overdose deaths, as well as emphasizing interdisciplinary care), the current 
investigation provides important information about physicians’ opioid prescribing and utilization 
of other professionals’ recommendations.  Based on the results, opioid prescribing was 
significantly influenced by the opioid risk evaluation conducted by the psychology team at the 
WVU Department of Family Medicine.  This information is promising for interdisciplinary 
treatment teams as it seems physicians integrate the professional assessment of other experts into 
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their decision making process.  Additionally, it suggests that physicians can modify their bias of 
prescribing based on age, ethnicity/race, and sex, as found in other studies, to instead rely on 
research-based opioid risk evaluations.  The opportunity for additional information in an area in 
which physicians often lack training and describe having difficulty providing treatment 
(Bendtsen, Hensing, Ebeling, & Schedin, 1999; Bertakis, Azari, & Callahan, 2003; Matthias et 
al., 2010) may allow for physicians to utilize information from other professionals to learn about 
alternative treatment options in the process. 
What remains unanswered by the current study is if this modification to utilize opioid risk 
status for prescribing is an improvement for patient care, a means to protect the physician from 
litigation, or a potential bias against patients that may have psychosocial problems?  Patients that 
are high risk for opioid abuse still can be prescribed opioid medication (Weaver & Schnoll, 
2002), but the inherent risks for the patient and physician increase resulting in increased scrutiny 
of the patient and intensified monitoring responsibilities for the physician.  The increased 
demand on physician time may lead physicians to simply deny prescriptions for those patients 
that may benefit, even if high risk.  Alternatively, the utilization of risk status and expert pain 
recommendations may encourage physicians to try alternative treatment options (e.g., 
antidepressant or anticonvulsant medication, physical therapy, psychotherapy) prior to 
prescribing opioid medication, which arguably is a better first line of treatment than chronic 
opioid therapy and may lead to improved patient functioning that is unlikely to be achieved with 
chronic opioid therapy alone.   
The current study illustrates the effectiveness of providing physicians with supplemental 
information, specifically in an area in which they tend to have less training and confidence (i.e., 
chronic pain treatment, identifying opioid abuse and diversion).  By utilizing risk status to aid 
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physician’s prescribing decisions, the inclusion of evidence-based factors into their decision-
making process is simplified.  Physicians can rely on the expert evaluation of a colleague, while 
potentially eliminating some of their own inherent bias and possibly improving patient care.  On 
a larger systems level, understanding how opioid risk status and other factors affect physicians’ 
opioid prescribing, may reveal how to modify physician bias not only in the realm of opioid 
prescribing, but other aspects of patient care.  If the inclusion of interdisciplinary care and 
collaborative treatment reduces physician bias and eases the decision-making process, it lends 
the physician more time to spend on other aspects of patient care or other cases.  With the influx 
of patients into primary care expected with the introduction of the Affordable Care Act, 
increasing physician efficiency and providing support is an essential part of helping to make this 
policy successful.  Thus, opioid risk evaluations demonstrate one aspect of support that 
psychology can provide to physicians and the healthcare system as a whole.              
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Table 1 
 
Frequencies and Percentages of Assigned Risk Status by Evaluator Training Level 
 
Risk Status Graduate 
Student  
Total (%) 
Predoctoral 
Intern 
Total (%) 
Postdoctoral 
Fellow  
Total (%) 
Licensed 
Psychologist 
Total (%) 
Low/Low-Moderate 13 (48.1) 9 (36.0) 6 (17.6) 22 (33.8) 
Moderate/Moderate-High 7 (25.9) 9 (36.0) 13 (38.2) 29 (44.6) 
High 7 (25.9) 7 (28.0) 15 (44.1) 14 (21.5) 
Total 27 (100/17.9)  25 (100/16.6)  34 (100/22.5)  65 (100/43.0)  
 
Note.  In the three risk status levels, the number in parentheses represents the percent within each 
column group (e.g., 48.1% = percent of Graduate Students with evaluation outcomes in the 
low/low-moderate risk category).  The numbers in parentheses for each Total reflect the group 
(column) total percentage, followed by the percentage of the overall total number of patients 
evaluated by each column group (e.g., 17.9% = percent of total patients evaluated by a Graduate 
Student).  
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Table 2 
 
Frequencies and Percentages of Psychological Evaluator/Physician Training Level by Opioid 
Prescribing 
 
Evaluator/Physician Training Level Yes, Prescribed Opioid 
Total (%) 
No, Not Prescribed Opioid 
Total (%) 
Graduate Student 17 (19.3) 10 (15.9) 
Predoctoral Intern 20 (22.7) 5 (7.9) 
Postdoctoral Fellow 20 (22.7) 14 (22.2) 
Licensed Psychologist 31 (35.2) 34 (54.0) 
Total 88 (100/58.3) 63 (100/41.7) 
   
Resident 32 (36.4) 17 (27.0) 
Attending 56 (63.6) 46 (73.0) 
Total 88 (100/58.3) 63 (100/41.7) 
 
Note.  For the variables in each row (i.e., psychologist training level followed by physician 
training level), the number in parentheses represents the percent within each column group (e.g., 
19.3% = percent of patients prescribed an opioid who had evaluations with a Graduate Student). 
The numbers in parentheses for each Total reflects the group (column) total percentage, followed 
by the percentage of the overall total number of patients prescribed or not prescribed an opioid 
(e.g., 58.3% = percent of total patients prescribed an opioid).  
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Table 3 
Inspecting Multicollinearity Assumption through Collinearity Statistics 
 Tolerance Variance Inflation Factor 
Sex .73 1.37 
Race .88 1.14 
Age .70 1.44 
Risk Status .46 2.17 
Abuse history .65 1.53 
Smoking status .78 1.29 
Substance abuse .58 1.71 
Family substance abuse history .71 1.40 
Employment status .75 1.33 
Relationship status .70 1.42 
Education .82 1.21 
Mental health diagnoses .84 1.19 
Pain diagnoses .90 1.11 
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Table 3 (continued) 
Inspecting Multicollinearity Assumption through Collinearity Statistics 
 
Tolerance Variance Inflation Factor 
Pain rating (0-10) .63 1.59 
Duration of chronic pain .73 1.36 
Physician sex .84 1.19 
Physician training level .87 1.15 
SFMPQ .61 1.65 
PCS .42 2.37 
PDI .62 1.60 
SOAPP-R .37 2.67 
TSK .56 1.80 
BDI-II .39 2.56 
Note. SFMPQ = Short Form-McGill Pain Questionnaire; PCS = Pain Catastrophizing Scale; PDI 
= Pain Disability Index; SOAPP-R = Screener and Opioid Assessment for Patients with Pain, 
Revised; TSK = Tampa Scale for Kinesiophobia; BDI-II = Beck Depression Inventory-II 
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Table 4 
Bivariate Correlations between Questionnaires 
 SF-MPQ PCS PDI SOAPP-R TSK 
PCS  .43**     
PDI .35** .44**    
SOAPP-R .33** .56** .33**   
TSK .28** .40** .40** .23*  
BDI-II .33** .50** .38** .65** .29** 
Note. * = significant at the <.05 level; ** = significant at the <.001 level; SFMPQ = Short Form-
McGill Pain Questionnaire; PCS = Pain Catastrophizing Scale; PDI = Pain Disability Index; 
SOAPP-R = Screener and Opioid Assessment for Patients with Pain, Revised; TSK = Tampa 
Scale for Kinesiophobia; BDI-II = Beck Depression Inventory-II 
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Table 5 
Missing Values by Self-Report Questionnaire 
Questionnaire Number of missing items (%) 
Short Form-McGill Pain Questionnaire 90 (3.9%) 
Pain Catastrophizing Scale 86 (4.4%) 
Pain Disability Index 43 (4.1%) 
Screener and Opioid Assessment for Patients with Pain-Revised 169 (4.7%) 
Tampa Scale for Kinesiophobia 209 (8.1%) 
Beck Depression Inventory-II 236 (7.4%) 
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Table 6 
Patient Characteristics and Predictor Variables Descriptive Statistics for Study Sample 
(Continuous Variables) 
 Mean Standard Deviation Minimum Maximum 
Age 48.2 11.1 19 80 
Pain rating  7.6 1.8 0 10 
Duration of pain (years) 10.7 9.5 .25 51 
Times married 1.5 1.1 0 7 
Children 2.3 1.7 0 10 
SFMPQ 21.4 9.7 0 45 
PCS 25.6 13.8 0 52 
SOAPP-R 17.2 11.3 0 74 
BDI-II 13.8 10.2 0 53 
PDI 40.4 15.0 0 70 
TSK 37.9 11.7 17 74 
 
Note. SFMPQ = Short Form-McGill Pain Questionnaire; PCS = Pain Catastrophizing Scale; 
SOAPP-R = Screener and Opioid Assessment for Patients with Pain, Revised; BDI-II = Beck 
Depression Inventory-II; PDI = Pain Disability Index; TSK = Tampa Scale for Kinesiophobia 
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Table 7 
Patient Characteristics and Predictor Variables Descriptive Statistics for Study Sample 
(Categorical Variables) 
 Total  Percentage 
Sex    
 Female 62 41.1% 
 Male 89 58.9% 
Race    
 White 146 96.7% 
 Black 5 3.3% 
Risk Status    
 Low/Low-Moderate 50 33.1% 
 Moderate/Moderate-High 58 38.4% 
 High 43 28.5% 
Employment    
 Employed 70 46.4% 
 Disabled 81 53.6% 
Relationship    
 Single/Divorced 84 55.6% 
 Married/Partnered 67 44.4% 
Smoking Status    
 Yes 90 59.6% 
 No 61 40.4% 
Abuse History    
 Yes 48 31.8% 
 No 93 61.6% 
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Table 7 (continued) 
 
Patient Characteristics and Predictor Variables Descriptive Statistics for Study Sample 
(Categorical Variables) 
  Total  Percentage 
Education    
 <High School 29 19.2% 
 High School/GED 65 43.0% 
 Associate’s/Some College 30 19.9% 
 Bachelor’s or higher 17 11.3% 
Substance Abuse History    
 Yes 57 37.7% 
 No 94 62.3% 
Family Substance Abuse History    
 Yes 58 33.8% 
 No 51 38.4% 
Physician Training Level    
 Resident 102 67.5% 
 Attending 49 32.5% 
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Table 8 
Differences in Demographic and Psychosocial Variables by Opioid Prescribing Group 
(Continuous Variables) 
 Not Prescribed 
Opioid  
M (SD) 
Prescribed 
Opioid 
M (SD) 
t (149) p 
Age 47.3 (11.2) 48.8 (11.0) -.80 .43 
Pain rating (0-10)*  8.0 (1.8) 7.4 (1.7) 1.95 .05 
Duration of pain (years) 10.6 (10.1) 10.8 (9.1) -.15 .88 
Times married 1.6 (1.3) 1.4 (1.0) 1.14 .26 
Children 2.4 (1.8) 2.2 (1.6) .65 .43 
SFMPQ 22.0 (9.8) 21.1 (10.0) .57 .57 
PCS 29.6 (12.4) 22.7 (14.1) 3.13 .002 
SOAPP-R 20.0 (13.4) 15.2 (8.9) 2.61 .009 
BDI-II 16.0 (12.6) 12.4 (8.4) 2.04 .04 
PDI 42.2 (13.7) 39.0 (16.2) 1.25 .21 
TSK 38.6 (10.6) 37.9 (9.9) .39 .70 
 
Note.  *Pain ratings measured from 0-10, with 10 being the worst pain; SFMPQ = Short Form-
McGill Pain Questionnaire; PCS = Pain Catastrophizing Scale; SOAPP-R = Screener and Opioid 
Assessment for Patients with Pain, Revised; BDI-II = Beck Depression Inventory-II; PDI = Pain 
Disability Index; TSK = Tampa Scale for Kinesiophobia 
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Table 9 
 
Differences in Demographic and Psychosocial Variables by Opioid Prescribing Group 
(Categorical Variables) 
 Not Prescribed 
Opioid  
Total (%) 
Prescribed 
Opioid 
Total (%) 
 p 
Sex      
 Female 36 (57.1) 53 (60.2) 
.05  .83 
 Male 27 (42.9) 35 (39.6) 
Race      
 White 59 (93.7) 87 (98.9) 
1.70 .19 
 Black 4 (6.3) 1 (1.1) 
Employment      
 Employed 26 (41.3) 44 (50.0) 
.80 .37 
 Disabled 37 (58.7) 44 (50.0) 
Relationship      
 Single/Divorced 43 (68.3) 41 (46.6) 
6.13 .01 
 Married/Partnered 20 (31.7) 47 (53.4) 
Smoking Status      
 Yes 40 (63.5) 50 (56.8) 
.43 .51 
 No 23 (36.5) 38 (43.2) 
Abuse History      
 Yes 27 (46.6) 21 (25.3) 
5.95 .02 
 No 31 (53.4) 62 (74.7) 
Substance Abuse      
 Yes 37 (58.7) 20 (22.7) 
18.75 <.001 
 No 26 (41.3) 68 (77.3) 
Note. For the variables in each row, the number in parentheses represents the percent within each 
column group (e.g., 57.1% = percent of females not prescribed an opioid). 
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Table 9 (continued) 
Differences in Demographic and Psychosocial Variables by Opioid Prescribing Group 
(Categorical Variables) 
  Not 
Prescribed 
Opioid  
Total (%) 
Prescribed 
Opioid 
Total (%) 
 p 
Family 
Substance Abuse 
     
 Yes 25 (62.5) 33 (47.8) 
1.64 .20 
 No 15 (37.5) 36 (52.2) 
Education      
 <High School 20 (33.3) 9 (11.1) 
10.75 .01 
 High School/GED 24 (40.0) 41 (50.6) 
 Associate’s/Some College 11 (18.3) 19 (23.5) 
 Bachelor’s or higher 5 (8.3) 12 (14.8) 
Pain Diagnoses      
 Musculoskeletal 26 (41.3) 38 (43.2) 
.28 .99 
 Headache/Musculoskeletal 15 (23.8) 19 (21.6) 
 Abdominal/Chest 8 (12.7) 13 (14.8) 
 Neuropathic/Musculoskeletal 7 (11.1) 9 (10.2) 
 Chronic Widespread Pain 7 (11.1) 9 (10.2) 
Mental Health 
Diagnoses 
     
 Yes 41 (65.1) 51 (58.0) 
.51 .47 
 No 22 (34.9) 37 (42.0) 
Note. For the variables in each row, the number in parentheses represents the percent within each 
column group (e.g., 62.5% = percent of patients with a family history of substance abuse not 
prescribed an opioid). 
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Table 10 
Percentages of Study Sample with Various Chronic Pain Conditions and Mental Health  
Diagnoses 
 
 Total (%) 
Chronic Pain Conditions   
 Musculoskeletal 64 (42.4%) 
 Headache/Musculoskeletal 34 (22.5%) 
 Abdominal/Chest 21 (13.9%) 
 Neuropathic/Musculoskeletal 16 (10.6%) 
 Chronic Widespread Pain 16 (10.6%) 
Mental Health Conditions Any condition 101 (66.9%) 
 Anxiety 65 (43.0%) 
 Depression 79 (52.3%) 
 Bipolar Disorder 8 (5.3%) 
 Psychotic Disorder 6 (4.0%) 
 ADHD 5 (3.3%) 
 
Note.  ADHD = Attention-Deficit Hyperactivity Disorder 
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Table 11 
 
Frequencies and Percentages for Opioid Prescribing Group and Risk Status 
 
 Prescribed Opioid 
Total (%) 
Not Prescribed Opioid 
Total (%) 
Low/Low-Moderate 43 (48.9) 7 (11.1) 
Moderate/Moderate-High 34 (38.6) 24 (38.1) 
High 11 (12.5) 32 (50.8) 
Total 88 (100/58.3) 63 (100/41.7) 
 
Note.  In the three risk status levels, the number in parentheses represents the percent within each 
column group (e.g., 48.9% = percent of patients prescribed an opioid in the low risk category). 
The number in parentheses for each Total reflects the group (column) total percentage, followed 
by the percentage of the overall total number of patients prescribed or not prescribed an opioid 
(e.g., 58.3% = percent of total patients prescribed an opioid).  
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Table 12 
Regression Model: Predicting Opioid Prescribing with Opioid Risk Status 
Predictor Variable Unstandardized 
Regression 
Coefficient (B) 
Standard Error Odds Ratio 
Exp (B) 
Significance 
Value (p) 
Risk Status 1.44 .27 4.22 <.001 
 
Note.  For this model, Cox & Snell R2 = .22, Nagelkerke R2 = .29. 
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Table 13 
Regression Models: Binary Logistic Regressions Predicting Opioid Prescribing with Single Significant Predictors 
Predictor Variable Unstandardized 
Regression 
Coefficient (B) 
Standard 
Error 
Odds Ratio 
Exp (B) 
Significance 
Value (p) 
Cox & Snell R2 / 
Nagelkerke R2 
Significance 
Value (p) 
Substance Abuse -1.58 .36 .21 <.001 .13/.17 <.001 
Abuse -.94 .37 .39 .01 .05/.06 .01 
Education .51 .20 1.66 .01 .05/.06 .01 
Relationship .90 .35 2.47 .009 .05/.06 .01 
SOAPP-R -.04 .02 .96 .02 .05/.06 .01 
PCS -.04 .01 .96 .003 .06/.08 .002 
BDI-II -.03 .02 .97 .045 .03/.04 .04 
 
Note.  SOAPP-R = Screener and Opioid Assessment for Patients with Pain, Revised; PCS = Pain Catastrophizing Scale; BDI-II = 
Beck Depression Inventory-II 
PREDICTING OPIOID PRESCRIBING BEHAVIOR      
     
90 
Table 14 
Regression Models: Binary Logistic Regressions Predicting Opioid Prescribing with Single Non-Significant Predictors 
Predictor Variable Unstandardized 
Regression 
Coefficient (B) 
Standard 
Error 
Odds Ratio 
Exp (B) 
Significance 
Value (p) 
Cox & Snell R2 
/ NagelkerkeR2 
Significance 
Value (p) 
Age .01 .02 1.01 .43 .004/.01 .42 
Sex .13 .34 1.14 .70 .001/.001 .70 
Employment -.35 .33 .70 .29 .01/.01 .29 
Mental Health Condition -.30 .34 .74 .38 .01/.01 .38 
Family Substance Abuse  -.60 .41 .55 .14 .02/.03 .14 
Smoking Status -.28 .34 .76 .41 .01/.01 .41 
Pain Category      .002/.002 .99 
 Headache/ 
Musculoskeletal 
-.14 .43 .87 .74   
 Abdominal/Chest .11 .52 1.11 .84   
 Neuropathic/ 
Musculoskeletal 
-.13 .57 .88 .82   
 Chronic Widespread Pain -.13 .57 .88 .82   
PCP Sex .21 .33 1.23 .53 .003/.003 .53 
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Table 14 (continued) 
Regression Models: Binary Logistic Regressions Predicting Opioid Prescribing with Single Non-Significant Predictors 
Predictor Variable Unstandardized 
Regression 
Coefficient (B) 
Standard 
Error 
Odds Ratio 
Exp (B) 
Significance 
Value (p) 
Cox & Snell R2 
/ Nagelkerke R2 
Significance 
Value (p) 
PCP Training  -.44 .36 .65 .23 .01/.01 .22 
SFMPQ -.01 .02 .99 .57 .002/.003 .63 
PDI -.01 .01 .99 .22 .01/.02 .19 
TSK -.01 .02 .99 .74 .001/.001 .56 
 
Note. PCP = Primary Care Physician; SFMPQ = Short Form McGill Pain Questionnaire; PDI = Pain Disability Index; TSK = Tampa 
Scale for Kinesiophobia 
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Table 15 
Regression Model: Predicting Opioid Prescribing with All Significant Predictors, excluding Risk 
Status 
Predictor Variable Unstandardized 
Regression 
Coefficient (B) 
Standard Error Odds Ratio 
Exp (B) 
Significance 
Value (p) 
Substance Abuse -1.37 .41 .26 .001 
Abuse -.63 .44 .53 .15 
Education  .37 .23 1.44 .11 
Relationship .63 .41 1.88 .13 
BDI-II -.004 .03 1.00 .90 
SOAPP-R -.01 .03 .99 .74 
PCS -.01 .02 1.00 .48 
 
Note.  For this model, Cox & Snell R2 = .19, Nagelkerke R2 = .26; BDI-II = Beck Depression 
Inventory-II; SOAPP-R = Screener and Opioid Assessment for Patients with Pain, Revised; PCS 
= Pain Catastrophizing Scale
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Table 16 
Regression Model: Predicting Opioid Prescribing with Substance Abuse and Opioid Risk Status  
Predictor Variable Unstandardized 
Regression 
Coefficient (B) 
Standard Error Odds Ratio 
Exp (B) 
Significance 
Value (p) 
Substance Abuse -.68 .43 .51 .11 
Risk Status 1.22 .30 3.40 <.001 
 
Note.  For this model, Cox & Snell R2 = .23, Nagelkerke R2 = .31
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Table 17 
 
Frequencies and Percentages for Primary Care Physician Training Level and Risk Status 
 
 Attending 
Total (%) 
Resident 
Total (%) 
Low/Low-Moderate 14 (28.6) 36 (35.3) 
Moderate/Moderate-High 20 (40.8) 38 (37.3) 
High 15 (30.6) 28 (27.5) 
Total 49 (100/32.5) 102 (100/67.5) 
 
Note.  In the three risk status levels, the number in parentheses represents the percent within each 
column group (e.g., 28.6% = percent of patients assigned low/low-moderate risk referred by 
attending physicians). The numbers in parentheses for each Total reflects the group (column) 
total percentage, followed by the percentage of the overall total number of patients referred by 
each training level (e.g., 32.5% = percent of total patients referred by attending physicians). 
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Appendix A 
Non-Opioid Treatments for Chronic Pain  
Pharmacological treatments.  Physician guidelines provide clear suggestions in the 
treatment of chronic pain based on intensity (Katz, 2008).  When treating mild pain, 
acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs; e.g., aspirin, naproxen) are 
recommended because there is a ceiling effect to the analgesia and they do not produce tolerance 
or physical dependence; however, there is increased risk for gastrointestinal ulcers, serious 
cardiovascular events, hypertension, acute renal failure, and worsening of preexisting heart 
failure (Vonkeman & van de Laar, 2010).  These adverse effects can be prevented by limiting 
NSAID dosage and duration.  Acetaminophen and NSAIDs are effective at relieving pain 
resulting from a variety of problems including trauma, arthritis, surgery, and cancer (Carr & 
Goudas, 1999; Zuckerman & Ferrante, 1998).  Treating moderate or severe chronic pain without 
opioids is more complicated.  Combination therapies can enhance the effects of non-opioid 
analgesics, especially when treating neuropathic pain, which is damage or disease affecting the 
somatosensory system (Guay, 2001).  The most effective adjuvant therapy is tricyclic 
antidepressants (Guay, 2001).  Tricyclic antidepressants are not FDA-approved for pain 
treatment; however, several studies have shown their effectiveness for arthritis, diabetic 
neuropathy, postherpetic neuralgia, tension headache, migraine, fibromyalgia, low back pain, and 
pelvic pain (Barkin, Schwer, & Barkin, 2007; Rosenquist, 2013).  A second adjunctive treatment 
is anticonvulsants, which are effective at relieving shooting pain associated with peripheral nerve 
damage (Guay, 2001).  Anticonvulsants are effective in alleviating the pain associated with 
fibromyalgia and neuropathic pain, with some support for use in patients with low-back pain due 
to radiculopathy (Attal et al., 2010; Dworkin et al., 2010; Crofford et al., 2005; Tan, Barry, 
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Reken, & Baker, 2010).  Skeletal muscle relaxants often are prescribed as adjuvant medications 
for short-term relief due to the sedative side effects.  The long term use of muscle relaxants has 
not been shown to be an effective treatment for chronic pain; however, they are superior to 
placebo for mild to severe muscle spasms often associated with a variety of pain conditions (See 
& Ginzburg, 2008).  Finally, topical agents have been utilized when the pain in localized and are 
advantageous in that the user can avoid systemic side-effects (Turk, Wilson, & Cahana, 2011).  
Topical agents have demonstrated effective pain relief as compared to placebo for neuropathic 
pain and musculoskeletal disorders (Mason et al., 2004).  These non-opioid pharmacological 
options provide health care providers with greater flexibility when treating chronic pain and are 
effective at alleviating mild to moderate pain (Guay, 2001).  
Interventional treatments.  Interventional treatments include anesthetic injection 
therapy, surgical intervention, and implantable devices, all with the purpose of locating an 
individual’s source of pain and providing pain relief (Turk et al., 2011).  Injection therapy 
utilizes nerve blocks,which deliver various anesthetics to nerves and muscles to interrupt pain 
messages in the body, reduce inflammation, or eliminate the neurons at the site of the pain (Turk 
et al., 2011).  The most common injection for pain management is an epidural steroid injection, 
which is most effective in patients with radiculopathy with prolapsed lumbar disc (i.e., nerve root 
damage, which can cause pain in the arms, hands, or feet) and less so in those with non-specific 
low-back pain (Chou, Atlas, Stanos, & Rosenquist, 2009; Manchikanti, 2004).  The second most 
common injection is the facet injection, which includes a long-lasting corticosteroid (e.g., 
triamcinolone or methylprednisolone) and an anesthetic numbing agent (e.g., lidocaine or 
bupivacaine; Manchikanti, 2004).  There are mixed findings in regard to the effectiveness of 
injections, especially for long-term use.  A review conducted by  Luijsterburg et al. (2007), 
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found injections were not shown to be clearly effective for use in lumbosacral radicular 
syndrome (i.e., low back pain that radiates into the buttock or down the leg); however, Chou and 
colleagues (2009) determined injections are useful in facet joint pain.  The general consensus in 
the literature is that the use of an injection treatment regimen is most effective for facet joint 
pain, discogenic low-back pain, and in radiculopathy with prolapsed lumbar discs (Chou et al., 
2009).  
Surgical intervention refers to procedures such as lumbar fusions, artificial disc 
replacement, discectomy for radiculopathy with herniated lumbar disc, decompressive 
laminectomy for spinal stenosis, and implantation of an interspinous spacer device (Turk et al., 
2011).  From 1990 to 2001, there has been an increase in spinal surgeries for chronic pain 
patients, with lumbar fusion procedures increasing 220% (Deyo, Gray, Kreuter, Mirza, & Martin, 
2005).  While the rate of surgeries has increased, the evidence supporting the effectiveness of 
spinal surgeries in pain reduction remains poor to fair.  Studies have found that there can be 
initial significant pain reduction; however, benefits diminish over time, with one study reporting 
41% of patients with no change or worsened quality of life approximately five years following 
the procedure (DeBerard, Masters, Colledge, Schleusener, & Schlegel, 2001; Fritzell, Hagg, 
Wessberg, & Nordwall, 2001).  For patients with chronic non-cancer pain, there are no 
guidelines that suggest which patients are most likely to benefit from spinal surgery, and as a 
result the outcomes on pain reduction are unpredictable.  
Another interventional treatment involves the implantation of electrodes or intrathecal 
drug delivery devices on or near the spine (Turk et al., 2011).  The electrodes act to inhibit pain 
signals by stimulating peripheral nerves, which modulate pain (Turk et al., 2011).  This 
technique has been shown to reduce pain, improve quality of life, reduce the use of analgesics, 
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and result in patients returning to work; however, these results are limited to selected patients 
with refractory neuropathic pain (Taylor, 2006).  Epidural and intrathecal devices provide 
targeted drug delivery, which enables patients to experience pain relief with a small fraction of 
an oral medication dose (Nance & Meythaler, 1999).  Turner, Sears, and Loeser (2007) 
conducted a systematic review and concluded that patients typically experience moderate 
reductions in pain and improvements in functioning; however, the long-term effectiveness is 
unclear.  Implantable devices should be considered after oral medication, surgery, and injection 
procedures have not provided adequate pain reduction due to the need for routine monitoring, 
high cost, and need for replacement and maintenance of devices (Turk et al., 2011).  
A less invasive alternative to intrathecal drug delivery devices is transcutaneous electric 
nerve stimulation.   This technique utilizes electrodes placed on the skin near the spine, which 
deliver electrical stimulation to reduce pain through nociceptive inhibition at the presynaptic 
level in the dorsal horn, limiting the transmission of pain signals (Nnoaham & Kumbang, 2008).  
Systematic reviews and meta-analyses resulted in mixed findings on the effectiveness for 
transcutaneous electric nerve stimulation on pain reduction, which in part is due to poor study 
methodology (Johnson & Martinson, 2007; Khadilkar, Odebiyi, Brosseau, & Wells, 2008; 
Nnoaham & Kumbang, 2008).  
Physical, rehabilitation, and psychological interventions.  Exercise interventions have 
been shown to decrease pain by approximately 30% and improve function by approximately 
20% (van Tulder, Malmivaara, Hayden, & Koes, 2007).  Exercise interventions also have been 
shown to affect work disability status, increasing returns to work (Schonstein, Kenny, Keating, 
& Koes, 2003; Oesch, Kool, Hagen, & Bachmann, 2010).  One problem with the success of these 
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interventions is patient adherence, which potentially can be mitigated through psychological 
intervention. 
The most common psychotherapeutic techniques utilized for chronic pain patients include 
cognitive-behavioral strategies (Turk et al., 2011).  Specific strategies commonly employed are 
coping techniques, cognitive restructuring, and relaxation techniques. The results of several 
meta-analyses and systematic reviews suggest that psychological treatment results in moderate 
improvements in pain reduction and physical and emotional functioning (Dixon, Keefe, Scipio, 
Perri, & Abernethy, 2007; Henschke et al., 2010; Hoffman, Papas, Chatkoff, & Kerns, 2007; 
Jensen & Patterson, 2006; Montgomery, DuHamel, & Redd, 2000; Morley, Eccleston, & 
Williams, 1999).  Because a portion of patients do not respond to cognitive-behavioral treatment, 
a second psychotherapeutic strategy of acceptance-based interventions has been employed for 
chronic pain patients. These techniques emphasize acceptance of the pain rather than attempting 
to fight or control it; to recognize and accept that the pain is a part of life and cannot be 
completely eliminated.  This approach utilizes mindfulness and meditation techniques to reduce 
stress and pain (Kabat-Zinn, 1990).  A systematic review and meta-analysis revealed that 
acceptance-based interventions are equivalent in effectiveness to cognitive-behavioral treatment, 
and may be a good alternative for those who do not respond to cognitive-behavioral techniques 
(Veehof, Maarten-Jan, Schreurs, & Bohlmeijer, 2011).  
Integration of physical and psychological treatments into a singular interdisciplinary pain 
rehabilitation program results in significant pain reduction (Guzman et al., 2001; Hoffman et al., 
2007; Morley et al., 1999) and a decrease in prescription pain medication usage (Hoffman et al., 
2007).  Other studies have reported significant reductions in health care use after rehabilitation 
programs (Flor, Fydrich, & Turk, 1992), and reduction in social transfers and benefits (i.e., 
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welfare benefits, sickness benefit, and pensions; Thomsen, Sorensen, Sjogren, & Eriksen, 2002), 
which has not been shown to be possible through pharmacological or invasive treatment 
(Nachemson, 1992).  Additionally, in two of the meta-analyses conducted, results suggest that 
the long-term effects on return to work for patients treated in an interdisciplinary rehabilitation 
program were superior to those of other active treatments (Flor et al., 1992; Hoffman et al., 
2007).   
Complementary and alternative interventions.  The most popular complementary and 
alternative treatments offered include spinal manipulations, massage therapy, and acupuncture.  
These techniques are not commonly associated with conventional medicine; however, research 
has demonstrated that these techniques are at least minimally effective in reducing pain (Turk et 
al., 2011).  Spinal manipulations (i.e., chiropractic adjustments) are most commonly used for 
low-back pain.  Based on two systematic reviews, researchers concluded that spinal 
manipulations are more effective than “placebo” spinal manipulations, bed rest, or traction (Tan 
et al., 2007).  Massage therapy seems to have benefits for low-back and shoulder pain and 
potentially beneficial for fibromyalgia and neck pain (Tan et al., 2007); however, it is difficult to 
draw conclusions because of the wide variations in massage techniques.  Of all of the 
complementary and alternative interventions, acupuncture has the most support for its use with 
chronic pain patients.  Acupuncture has been shown to be effective for the treatment of chronic 
low-back pain (Furlan et al., 2005; Haake et al., 2007; Manheimer, White, Berman, Forys, & 
Ernst, 2005; Witt, Ludtke, Wegscheider, & Willich, 2010) with possible pain reduction benefits 
for fibromyalgia and neck pain (Gilron & Max, 2001).  While acupuncture helps to reduce pain, 
it has not been shown to be effective in improving functioning, physically or emotionally (Turk 
et al., 2011).          
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Appendix B 
Flow sheet for Chronic Opioid Therapy: WVU Department of Family Medicine 
NEW PATIENTS TO CLINIC: 
 No opioids written at first visit 
 Explain process to patients and give information sheet on narcotics prior to check out 
PRIOR TO PRESCRIBING OPIOIDS: 
 Previous records received from provider and reviewed 
 Urine drug screen  
 Physical exam and review of diagnostic studies 
 Diagnosis of pain condition determined  
 WV Board of Pharmacy review  
 Refer to Family Medicine psychologists for pain evaluation 
PAIN ASSESSMENT (BY PSYCHOLOGIST) 
 Self-report questionnaires assess: 
 Quality, intensity, and duration of pain  
 Functioning affected by pain 
 Negative cognitions about pain 
 Fear of activity and movement 
 Risk for future misuse of opioids   
 Current behaviors indicating medication misuse 
 Mood 
 Clinical Interview 
 Pain triggers 
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 Goals for pain and function 
 Impact of pain on functioning  
 Pain treatment history 
 Social and family history 
 Substance abuse history for patient and family 
IF PRESCRIBING OPIOID… 
 Controlled substance agreement signed 
 Treatment plan includes non-opioid options (PT, TCA, anti-seizure med, Tai Chi, CBT) 
 Document plan in chart  
 All controlled substances scripts printed electronically 
 No other CNS depressants (i.e, Benzodiazepines or ETOH) 
 If resident physician, inform attending 
PERIODIC ASSESSMENT FOR ALL PATIENTS ON CHRONIC OPIOIDS  
 Random Drug Screen every 4-6 months or as physician requests 
 Pain, functioning, mood measures 
 Verify adherence to all treatment (not solely opioids) 
 Verify that patient is not receiving opioids from other providers or locations (review 
Electronic Medical Records 
 Board of Pharmacy required at least annually
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Appendix C 
Demographics Form 
Today’s date:_______________ 
 
NAME:_____________________________     DATE OF BIRTH:__________________     AGE:___________ 
 
Are you: (Circle one)       Single       Married       Separated       Divorced       Widowed    
        
Number of Children: _____________             How many times have you been married?_________ 
 
If married, Spouse’s occupation: _______________________________________________________________ 
 
Are you  (circle one):    Working      Retired      Disabled      Student      Volunteering       Other_____________   
 
What type of work do you do?_________________________________________________________________ 
 
Person to contact in emergency :_______________________         Phone: ______________________________ 
 
Who lives with you? ________________________________________________________________________ 
 
If we need to contact you, is it OK to call you at home? _____________                Work?______________ 
 
Is it OK to leave a message?_________________          If yes, at what number?__________________________ 
 
Family Doctor: _____________________________________________________________________________ 
 
List of Medications:_________________________________________________________________________ 
__________________________________________________________________________________________ 
 
Reason for visit today? _______________________________________________________________________ 
 
How long has pain been a problem for you?______________________________________________________ 
 
Which of these techniques have you already tried? How much did it help?  
 1 
(none) 
2 3 
(some) 
4 5 
(a lot) 
Physical Therapy      
Surgery      
Medication      
Massage      
Exercise      
Tai Chi/Yoga      
Chiropractor      
 
Caffeine use (Circle all that apply):        Coffee           Tea               Soda                 No-Doz 
 
Alcohol use: Daily________ Weekly________Monthly_______   How much?______________ 
 
Nicotine Use:   Cigarettes/day:__________ Packs/day_________ Years Used______________ 
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 Have you ever tried to quit?    Yes________      No________ 
 Would you like to try to quit?  Yes________      No________ 
 
Is alcohol or drug use causing you any problems in your life?  Yes_______   No________ 
 
Have you ever tried to hurt yourself?        Yes________  (When?____________________)    No______ 
Are there guns in your home?          Yes________   No________ 
 
 
Highest Grade Completed:____________________________________________________________________ 
 
Where were you raised?_________________________         Who raised you?________________________ 
 
How long have you lived in this area?___________________________________________________________ 
 
Was there any violence in your home when you were a child?________________________________________ 
 
Do you have a religious affiliation? YES______         NO_____   
 
If yes, how often do you attend church services?___________________________________________________ 
 
Are there any cultural or ethnic issues that would be important for me to understand about you? YES_____   
NO_____      _______________________________________________________________________________ 
 
Have you ever served in the military?  YES_______     NO_______ 
 
What do you do for fun?______________________________________________________________________ 
 
Please place an X in the NOW column for any of the following symptoms you are currently having, and place 
an X in the PAST column for any of the symptoms you have had in the past. 
 
NOW  PAST      NOW PAST 
____ ____ Sad Most of the Time   ____ ____ Mood Swings 
____ ____ Loss of Energy    ____ ____ Too Much Energy 
____ ____ Not Enjoying Things   ____ ____ Spending Too Much Money 
____ ____ Loss of Sex Drive   ____ ____ Feeling Nervous 
____ ____ Excessive Sleep   ____ ____ Difficulty with Sleep  
____ ____ Hearing voices in your head        ____ ____ Angry Outbursts                                  
____ ____ Worry too much   ____ ____ Unusual thoughts   
____ ____ Problems Concentrating                          ____ ____ Panic attacks 
____ ____ Feeling Shaky    ____ ____ Thoughts you can’t get out of your head 
____ ____ Don’t want to live   ____ ____ Feeling like you’re being watched or followed  
 
If you could change 3 things about yourself or your situation, what would you pick? 
1) Most important: ______________________________________________________________________ 
2) Next important: ______________________________________________________________________ 
3) Important:         _______________________________________________________________________ 
 
Is there anything else you would like us to know about you or your situation?____________________________ 
 
PREDICTING OPIOID PRESCRIBING BEHAVIOR      
     
105 
Appendix D 
Short Form-McGill Pain Questionnaire 
Some of these words describe your present pain. Please mark an intensity rating for each word. If a word 
does not describe your pain, rate it “0” (none). If a word does describe your pain, rate the intensity of that 
quality with “1” (mild), “2” (moderate), or “3” (severe). Make your rating by placing a mark in the 
appropriate box. 
 None 
(0) 
Mild 
(1) 
Moderate 
(2) 
Severe 
(3) 
1. Throbbing     
2. Shooting     
3. Stabbing     
4. Sharp     
5. Cramping     
6. Gnawing     
7. Hot-Burning     
8. Aching     
9. Heavy     
10. Tender     
11. Splitting     
12. Tiring-Exhausting     
13. Sickening     
14. Fearful     
15. Punishing-Cruel     
 
Mark the intensity of your present pain on the following scale: 
No Pain (0) 
Mild  (1) 
Discomforting (2) 
Distressing (3) 
Horrible (4) 
Excruciating  (5) 
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Appendix E 
Pain Disability Index 
The rating scales below are designed to measure the degree to which several aspects of your life are presently 
disrupted by persistent pain. In other words, we would like to know how much your pain is preventing you from 
doing what you would normally do, or from doing it as well as you normally would. Respond to each category 
by indicating the overall impact of pain in your life, not just when the pain is at its worst.  
 
For each of the 7 categories of life activity listed, please circle the number on the scale which describes the level 
of disability you typically experience. A score of 0 means no disability at all, and a score of 10 signifies that all 
of the activities in which you would normally be involved have been totally disrupted or prevented by your 
pain.  
 
                                                                                                   No                                                                               Total 
                                                                                               Disability                                                                    Disability 
1. Family/Home Responsibilities 
            This category refers to activities related to the home 
or family. It includes chores or duties performed 
around the house (e.g., yard work) and errands or 
favors for other family members (e.g., driving the 
children to school).  
0 1 2 3 4 5 6 7 8 9 10 
2. Recreation 
            This category includes hobbies, sports, and other 
leisure time activities.  
0 1 2 3 4 5 6 7 8 9 10 
3. Social Activity 
            This category refers to activities which involve 
participation with friends and acquaintances other 
than family members. It includes parties, theatre, 
concerts, dining out, and other social functions.  
0 1 2 3 4 5 6 7 8 9 10 
4. Occupation 
            This category refers to activities that are part of or 
directly related to one’s job. This includes non-
paying jobs such as that of a housewife or volunteer 
work.  
0 1 2 3 4 5 6 7 8 9 10 
5. Sexual Behavior 
            This category refers to the frequency and quality of 
one’s sex life.  
0 1 2 3 4 5 6 7 8 9 10 
6. Self-Care 
            This category includes activities which involve 
personal maintenance and independent daily living 
(e.g., taking a shower, getting dressed, etc.). 
0 1 2 3 4 5 6 7 8 9 10 
7. Life-Support Activity 
            This category refers to basic life-supporting 
behaviors such as eating, sleeping, and breathing.  
0 1 2 3 4 5 6 7 8 9 10 
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Appendix F 
Pain Catastrophizing Scale 
Everyone experiences painful situations as some point in their lives. Such experiences may include headaches, tooth pain, joint or muscle pain. 
People are often exposed to situations that may cause pain such as illness, injury, dental procedures, or surgery. 
We are interested in the types of thoughts and feelings that you have when you are in pain. Listed below are 13 statements describing different 
thoughts and feelings that may be associated with pain. Using the following scale, please circle the degree to which you have these thoughts and 
feelings when you are experience pain.  
 Not  
at All 
To a 
Slight Degree 
To a Moderate 
Degree 
To a 
Great Deal 
All the 
time 
1. I worry all the time about whether the pain will end. 0 1 2 3 4 
2. I feel I can’t go on. 0 1 2 3 4 
3. It’s terrible and I think it’s never going to get any better. 0 1 2 3 4 
4. It’s awful and I feel that it overwhelms me. 0 1 2 3 4 
5. I feel I can’t stand it anymore. 0 1 2 3 4 
6. I become afraid that the pain will get worse. 0 1 2 3 4 
7. I keep thinking of other painful events. 0 1 2 3 4 
8. I anxiously want the pain to go away. 0 1 2 3 4 
9. I can’t seem to keep it out of my mind. 0 1 2 3 4 
10. I keep thinking about how much it hurts. 0 1 2 3 4 
11. I keep thinking about how badly I want the pain to stop. 0 1 2 3 4 
12. There’s nothing I can do to reduce the intensity of the pain. 0 1 2 3 4 
13. I wonder whether something serious may happen. 0 1 2 3 4 
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Appendix G 
Tampa Scale for Kinesiophobia  
 
Please read each of the following statements and mark the number that better represents your feelings. 
 Strongly 
Disagree 
Somewhat 
Disagree 
Somewhat 
Agree 
Strongly 
Agree 
1. I’m afraid that I might injure myself if I exercise. 1 2 3 4 
2. If I were to try and overcome it, my pain would increase. 1 2 3 4 
3. My body is telling me I have something dangerously 
wrong. 
1 2 3 4 
4. My pain would probably be relieved if I were to exercise. 1 2 3 4 
5. People aren’t taking my medical condition seriously 
enough. 
1 2 3 4 
6. My accident has put my body at risk for the rest of my 
life. 
1 2 3 4 
7. Pain always means I have injured my body. 1 2 3 4 
8. Just because something aggravates my body does not 
mean it is dangerous. 
1 2 3 4 
9. I am afraid that I might injure myself accidently. 1 2 3 4 
10. Simply being careful that I do not make any unnecessary 
movements is the safest thing I can do to prevent my pain 
from worsening. 
1 2 3 4 
11. I wouldn’t have this much pain if there weren’t something 
potentially dangerous going on in my body. 
1 2 3 4 
12. Although my condition is painful, I would be better off if 
I were physically active. 
1 2 3 4 
13. Pain lets me know when to stop exercising so that I don’t 
injure myself. 
1 2 3 4 
14. It’s really not safe for a person with a condition like mine 
to be physically active.  
1 2 3 4 
15. I can’t do all the things normal people do because it’s too 
easy for me to get injured. 
1 2 3 4 
16. Even though something is causing me a lot of pain, I don’t 
think it’s actually dangerous. 
1 2 3 4 
17. No one should have to exercise when s/he is in pain. 1 2 3 4 
PREDICTING OPIOID PRESCRIBING BEHAVIOR      
     
109 
Appendix H 
Screener and Opioid Assessment for Patients with Pain-Revised 
 Never Seldom Some-
times 
Often Very 
Often 
1. How often do you have mood swings? 0 1 2 3 4 
2. How often have you felt the need for higher doses of medication to treat your pain? 0 1 2 3 4 
3. How often have you felt impatient with your doctors? 0 1 2 3 4 
4. How often have you felt that things are just too overwhelming that you can’t handle them? 0 1 2 3 4 
5. How often is there tension in the home? 0 1 2 3 4 
6. How often have you counted pain pills to see how many are remaining? 0 1 2 3 4 
7. How often have you been concerned that people will judge you for taking pain medication? 0 1 2 3 4 
8. How often do you feel bored? 0 1 2 3 4 
9. How often have you taken more pain medication than you were supposed to? 0 1 2 3 4 
10. How often have you worried about being left alone? 0 1 2 3 4 
11. How often have you felt a craving for medication? 0 1 2 3 4 
12. How often have others expressed concern over your use of medication? 0 1 2 3 4 
13. How often have any of your close friends had a problem with alcohol or drugs? 0 1 2 3 4 
14. How often have others told you that you had a bad temper? 0 1 2 3 4 
15. How often have you felt consumed by the need to get pain medication? 0 1 2 3 4 
16. How often have you run out of pain medication early? 0 1 2 3 4 
17. How often have others kept you from getting what you deserved? 0 1 2 3 4 
18. How often in your lifetime have you had legal problems or been arrested? 0 1 2 3 4 
19. How often have you attended an AA or NA meeting? 0 1 2 3 4 
20. How often have you been in an argument that was so out of control that someone got hurt? 0 1 2 3 4 
21. How often have you been sexually abused? 0 1 2 3 4 
22. How often have others suggested that you have a drug or alcohol problem? 0 1 2 3 4 
23. How often have you had to borrow pain medications from your family or friends? 0 1 2 3 4 
24. How often have you been treated for an alcohol or drug problem? 0 1 2 3 4 
 
